Max Wicha, MD 1

CURRICULUM VITAE

Max S. Wicha, M.D. EDUCATION High School: Bayside High School; Bayside, New York, 9/1962-6/1966 Undergraduate: State University of NY at Stony Brook, Biology, 9/1966-6/1970, B.S. Graduate/ Stanford University School of Medicine, California, Medicine, Professional: 9/1970-5/1974, M.D. POSTDOCTORAL TRAINING Intern: Internal Medicine, University of Chicago Hospitals and Clinics, Chicago,

6/1974-6/1975 Junior/Senior Internal Medicine, University of Chicago Hospitals and Clinics, Chicago, Resident: 7/1975-6/1977 Fellow: Clinical Oncology Fellow, National Cancer Institute, NIH, Bethesda,

7/1978-6/1980 Research Laboratory of Pathophysiology, National Cancer Institute, NIH, Bethesda, Associate: 7/1977-6/1979 Investigator: Laboratory of Pathophysiology, National Cancer Institute, NIH, Bethesda,

7/1979-6/1980 ACADEMIC APPOINTMENTS Assistant Professor, Internal Medicine, Division of Hematology and Oncology, University of

Michigan, Ann Arbor, Michigan, 7/1980-8/1983 Member, Tumor Metastasis and the Extracellular Matrix Program, 7/1982-present Member, Reproductive Endocrinology Program, University of Michigan, 7/1982-present Associate Professor, Department of Internal Medicine, Division of Hematology and Oncology,

University of Michigan 9/1983-8/1988 Director, Division of Hematology and Oncology, University of Michigan 12/1984-4/1993 Director, Simpson Memorial Research Institute, University of Michigan, 12/1984-4/1993 Member, Program in Cellular and Molecular Biology, University of Michigan, 7/1984-present Founding Director, University of Michigan Comprehensive Cancer Center, 6/1986-1/2015 Professor, Internal Medicine, Division of Hematology and Oncology, University of Michigan,

Ann Arbor, Michigan, 9/1988-present Member, Center for Molecular Medicine and Genetics, 7/1994-present Distinguished Professor of Oncology, University of Michigan, 2/1998-2014 Deputy Director of the Taubman Institute, University of Michigan, 1/2014-2017 Director, Forbes Institute for Cancer Discovery, University of Michigan 6/2016-present SCIENTIFIC ADVISORY BOARDS, SITE VISIT COMMITTEES, STUDY SECTIONS NCI Site Visit Team, University of California Cancer Research Laboratory, Berkeley, California,

1985

Max Wicha, MD 2

NIH Cell Biology and Physiology Study Section, Ad Hoc Member, 1985, 1986 NCI Site Visit Team, Norris Cotton Dartmouth Cancer Center, 1989 NCI Site Visit Team, Howard University, Washington, D.C., 1989 NCI Site Visit Team, Howard University Parent Committee, Washington, D.C., 1989 Scientific Advisor, University of Colorado Cancer Center, Denver, CO., 1990-1994 NIH Study Section, Bethesda, MD, March 1991, June 1991, November 1991 NCI Advisory Panel, Bethesda, MD, November 1991 Scientific Advisory Committee, Norris-Cotton Cancer Center, Dartmouth-Hitchcock Medical

Center, Hanover, NH, 1993-1994 Scientific Advisory Board, Michigan Cancer Foundation, Detroit, MI, 1993-1994 NCI Site Visit Team, MD Anderson Cancer Center, Houston, TX, 1992 NCI SPORE in Prostate Cancer Study Section, 1992 NCI Site Visit Chair, Jefferson Cancer Center, Philadelphia, PA, 1992 NCI Site Visit Chair, Duke University Cancer Center, Durham, NC, 1993 NCI Site Visit Chair, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, 1993 NCI Site Visit Chair, Columbia University Cancer Center, NY, NY, 1994 NCI Site Visit Chair, University of Alabama Cancer Center, Birmingham, Ala, 1994 NCI Site Visit Chair, Roswell Park Cancer Center, Buffalo, NY, 1994 NCI Site Visit Chair, City of Hope Cancer Center, Duarte, CA, 1995 NCI Site Visit Chair, University of Colorado Cancer Center, Denver, CO, 1995 NCI Program Project Site Visit Team, Biologic Modifiers of Breast Cancer, Hershey Cancer

Center, Hershey, PA, 1996 Scientific Advisory Board, Michigan State University Cancer Center, E Lansing, MI, 1991 Extramural Scientific Advisory Board-Chair; Chao Family Comprehensive Cancer Center,

University of California, Irvine; Orange, CA 1992-1999 Scientific Advisory Committee-Chair, V.T. Lombardi Cancer Research Center, Georgetown

University, Washington, D.C., 1992-2001 External Advisory Committee-Chair, University of Minnesota Cancer Center, 1995-2001 Scientific Advisory Board, St. Jude’s Cancer Center, Memphis, TN, 1995-2000 External Advisory Committee-Chair; University of Massachusetts Cancer Center, Worcester,

MA, 1997-2000 NCI Cancer Centers Review Panel, 1996 NCI Breast Cancer Program Review Group, 1996-1999 President’s Cancer Panel; Panel member, Buffalo, NY, 1998 NCI Site Visit Chair, Huntsman Cancer Center, Salt Lake City, Utah, 1998 Advisory Committee for Cancer Center Director, U of Virginia Health Sciences Center,

Charlottesville, VA, 1998 External Advisory Committee, City of Hope Comprehensive Cancer Center, Duarte, CA, 2000- External Advisory Committee, Purdue Cancer Center, West Lafayette, IN, 2000-2003 NCI Site Visit Team, Norris Cancer Center, University of Southern California; Los Angeles, CA,

June 2000 Member, NCI Scientific Review Group – Subcommittee C: Basic and Preclinical Sciences,

August 2001 External Advisory Committee, Long Island Cancer Center, Stony Brook State University of New

York, 2002 NCI Site Visit Team, Jonsson Comprehensive Cancer Center, Los Angeles, CA, 2002

Max Wicha, MD 3

NCI Site Visit Team, Roswell Park Cancer Institute, Buffalo, NY, 2003 NCI Site Visit Team, Fox Chase Cancer Center, Philadelphia, PA 2005 External Advisory Committee, The Wistar Institute, Philadelphia, PA 2002-2007 Scientific Advisory Board, Derald H Ruttenberg Cancer Center, Mt Sinai, NY, 1999-2007 Chairman, External Advisory Committee, The Cancer Institute of New Jersey, New Brunswick,

NY, 2004-2013 Chairman, External Advisory Committee, Dana Farber-Harvard Cancer Center, Boston, MA,

2006-present Chairman, External Scientific Advisory Committee, Norris Cotton Cancer Center, Lebanon, NH,

2006-present Chairman, External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY, 2006-present External Advisory Committee, Gene Therapy of Cancer Program Project, MD Anderson Cancer

Center, Houston, TX, 1992-2011 Scientific Advisory Committee, University of Texas, San Antonio Cancer Center, 1992-2012 Scientific Advisory Board-Chair, University of Miami Sylvester Comprehensive Cancer Center,

Miami, FL, 1991-2012 Scientific Advisory Board-Chair; Samuel Waxman Cancer Research Foundation, The Mount

Sinai Medical Center, New York, NY 1988-2010 External Advisory Committee, Winship Cancer Institute, Emory University School of Medicine;

Atlanta, GA, 2000- 2010 External Advisory Committee, University of Florida Shands Cancer Center; Gainesville, FL,

2000- 2012 Scientific Advisory Board Committee, Huntsman Cancer Center, Salt Lake City, UT, 2005-2015 External Advisory Board-Chair; Lurie Cancer Center, Northwestern Univ, Chicago, ILL, 1996-

present Scientific Advisory Board Committee, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

2008-present External Advisory Board Committee, USC Norris Cancer Center, Los Angeles, CA, 2012-2017 Scientific Review Committee, AACR Grants for Translational Breast Cancer Research, 2013-

present Scientific Advisory Board Committee, Pfizer, La Jolla, CA 2008-2011 Scientific Advisory Board, Oncomed, Redwood City, CA, 2004-2012 Scientific Advisory Board Committee, MedImmune, Gaithersburg, MD, 2011-present Scientific Advisory Board Committee, Verastem, Cambridge, MA, 2012-present Scientific Advisory Board Committee, Schulz Foundation, Minneapolis, MN, 2014-present Scientific Advisory Board Committee, Roche, Hoboken, NJ, 2014-present External Scientific Advisory Board, Van Andel Research Institute, Grand Rapids, MI, 2015-

present Board of Trustees, Van Andel Research Institute, Grand Rapids, MI, 2015-present Member, SARC Sarcoma SPORE External Advisory Board 2016-present SCIENTIFIC ACTIVITIES Editorial Boards: Blood, Molecular and Cellular Differentiation, Journal of Laboratory and Clinical Medicine 1994-1998, Cancer Research Assoc Editor 1993-2001, Oncology, Cancer Prevention International, Neoplasia, Clinical Cancer Research Assoc Editor 2000-2007,

Max Wicha, MD 4

American Journal of Oncology Review 2002-2007, Senior Editor Cancer Research 2009-Present; Breast Cancer Research Series Editor 2014 Reviewer: Nature, Science, Proceedings of the National Academy of Sciences (USA), Journal of Clinical Investigation, Journal of Cell Biology, Experimental Cell Research, Experimental Hematology, Cancer, Clinical and Experimental Metastasis, Journal of the National Cancer Institute, Tissue & Cell, American Institute of Biological Sciences, American Journal of Pathology, Journal of Immunology, Journal of Investigative Medicine, Journal of Medical Sciences, National Science Foundation, Oncology Research, Laboratory Investigation, Breast Cancer Research and Treatment, Molecular Pharmacology, Clinical Cancer Research, Surgery, Society for Experimental Biology and Medicine, Cell Death and Differentiation, Journal of Leukocyte Biology, Cancer Letters, Cancer Research, Cell Stem Cell Current Grant Support: I.D. Number: R35CA197585-01 National Institutes of Health/National

Cancer Institute Outstanding Investigator Award Role: Principal Investigator Effort: 6.0 calendar months Title: Targeting breast cancer stem cells Total Project Period: 02/01/16-01/31/23 Annual Direct Cost: $600,000 I.D. Number: U01 National Institutes of Health Role: Co-Investigator Effort: 0.36 calendar months Title: Environmental Regulation of Cancer Stem Cell Plasticity in Metastasis Total Project Period: 04/01/17-03/31/22 Annual Direct Cost: $499,436 I.D. Number: R56CA203290-01 National Institutes of Health Role: Principal Investigator Effort: 1.8 calendar months Title: Tunable Polymer-Graphene Oxide Composite for Single Cell Analysis

of Breast Cancer CTCs & CSCs Total Project Period: 09/21/16-08/31/17 Annual Direct Cost $193,548 ID. Number: BCRF-17-170 Breast Cancer Research Foundation (BCRF) Role: Principal Investigator Effort: 0.6 calendar months Title: Molecular Analysis of Breast Cancer Stem Cells at Single Cell

Resolution Total Project Period 10/1/17-09/30/2018 Annual Direct Cost S208,333 I.D. Number: N021378 MedImmune Role: Co-Investigator Effort: 0.3 calendar months Title: Analyzing Medimmune human HER2-targeted antibody drug

conjugate (ADC) in a human transgenic mouse model Total Project Period: 03/13/16-03/12/18 Annual Direct Cost: $190,000 I.D. Number: N021453 MedImmune Role: Principal Investigator Effort: 0.3 calendar months

Max Wicha, MD 5

Title: Investigating CSC and TIL responses in IMT treated syngeneic mouse models

Total Project Period: 05/26/16-05/25/19 Annual Direct Cost: $681, 919 Pending Grant Support: I.D. Number: R01 grant National Institutes of Health Role: Principle Investigator Effort 0.6 calendar months Title: Cancer Stem Cell Niche in Solid Tumors Total Project Period: 07/01/2017-06/30/2022 Annual Direct Cost: $497,953 Past Grant Support: I.D. Number: BCRF-16-169 Breast Cancer Research Foundation Role: Principal Investigator: Effort: 0.48 calendar months Title: Molecular Analysis of Breast Cancer Stem Cells at Single Cell

Resolution Total Project Period: 10/01/16-09/30/17 Annual Direct Cost: $208, 333 I.D. Breast Cancer Research Foundation Role: Principal Investigator: Effort 1.2 calendar months Title: Molecular Analysis of Single Circulating CSCs using the C1 and

BioMark HD Systems Total Project Period: 10/1/15-09/30/16 Annual Direct Cost: $200,000 I.D. Taubman Scholar Award Role: Principal Investigator Effort .36 calendar months Title: Proposal to Develop a Program in Cancer Stem Cell Research Total Project Period: 01/01/08-12/31/16 Annual Direct Cost: $50,000 Contracts: Company: MedImmune Role: Principal Investigator Effort 0 calendar months Title: Targeting EMT and MET States of Breast Cancer Stem Cells and its Therapeutic Utility in Overcoming Trastuzumab Resistance Total Project Period: 09/01/2014-08/31/2016 Annual Direct Cost: $225,080 PATENTS FILED: “Antibodies to Human Mammary Cell Growth Inhibitor and Methods of Production and Use” “Human Mammary Cell Growth Inhibitor and Methods of Production and Use” “Cancer Stem Cells”

Max Wicha, MD 6

“Isolation and Use of Solid Tumor Stem Cells” “Purification of a Breast Cancer Tumor Initiating (Stem) Cell” “An Efficient Xenograft Human Epithilial Cancer Model” “Breast Cancer Stem Cells and Notch Signaling” “Self-renewal of Human Mammary Stem Cells” “Targeting the Notch Signaling Pathway in Breast Cancer Stem Cells” “A Marker of Normal and Cancer Human Colonic Stem Cells” “Identification of Human Pancreatic Cancer Stem Cells” “New Marker and Potential Therapeutic for Cancer Stem Cells” “Anti-CXCR1 Compositions and Methods” “Nanoemulsion Therapeutic Compositions and Methods of Using the Same” COMPANIES Co-founder, OncoMed Pharmaceuticals, 2004; IPO, 2013 CERTIFICATION AND LICENSURE Michigan Medical License 42541; Illinois Medical License 36-51495; American Board of

Internal Medicine, Certified 1977; Certification in Medical Oncology, 1983 MILITARY SERVICE July 1977-May 1980, U.S. Public Health Service HONORS AND AWARDS National Science Foundation Research Award; S.U.N.Y. at Stony Brook, 1969 Woman’s Club Graduation Award; S.U.N.Y. at Stony Brook, 1970 B.S., Summa Cum Laude, Honors in Biology; Salutatorian, S.U.N.Y., 1970 Eli Luke and David Jacob Research Award; Stanford University School of Medicine, 1974 Upjohn Achievement Award for Excellence in Medicine; Outstanding Medical Resident Award;

University of Chicago Hospitals, 1977 Jerome Conn Award for Excellence in Research, 1983 Who’s Who in Science and Engineering, 1994 The Best Doctors in America: Midwest Region, 1994-2001 American Cancer Society Honoree, 1999 Fellow, American Association for the Advancement of Science, 2000 AACR Distinguished Lectureship in Breast Cancer Research, 2016 JE Wallace Sterling Lifetime Achievement Award in Medicine, 2017 MEMBERSHIP AND OFFICES IN PROFESSIONAL SOCIETIES American Association for Cancer Research American Federation for Clinical Research American Association for the Advancement of Science

Max Wicha, MD 7

American Society for Cell Biology American Society of Hematology Association of American Cancer Institutes, Chair Board of Directors 1999-2001 American Society for Clinical Investigation American Society of Clinical Oncology American Society for Clinical Research Michigan Society of Hematology and Oncology Southwest Oncology Group Association of American Physicians TEACHING ACTIVITIES Attending Physician, Medical Oncology In-Patient and Consultation Services; General Medicine

In-Patient Service; University of Michigan Hospitals, 1980-present Faculty member, Graduate Program in Cellular and Molecular Biology, University of Michigan,

1984-present American College of Physicians Oncology Review Course, Wayne State University, 1991 PhD Dissertation Committee, Gordon Saxe, 1992 PhD Dissertation Committee, Cheryl Jankowski, 1992 PhD Dissertation Committee, Peter Lee, 1993 PhD Dissertation Committee, Paul Ervin, 1994 PhD Dissertation Committee, Mary Benedict, 1995 Faculty member, Oncology Sequence, University of Michigan Medical Education, 1996, 1997 Faculty member, Cancer Biology Course, 1996, 1997 PhD Dissertation Committee, Cynthia van Golen, 1998 PhD Dissertation Committee, Gary Meyer, 2000 PhD Dissertation Committee, Andrew Hass, 2003 PhD Dissertation Committee, Sudha Krishnamurthy, 2010 PhD Dissertation Committee, Dang Vu, 2009, 2013 PhD Dissertation Committee, Sarah McDermott, 2015 PhD Dissertation Committee, Evelyn Jiagge, 2015 PhD Dissertation Committee, Joseph Nguyen, 2015 PhD Dissertation Committee, Hayley Paholak, 2015 PhD Dissertation Committee, Grace Bushnell, 2016 PhD Dissertation Committee, Christie Rodriguez Ramirez, 2016 COMMITTEES AND ADMINISTRATIVE SERVICES - University of Michigan Cancer Research Committee, 1981-2007 Dean’s Advisory Council, 1988-2007 Member, Scientific Advisory Board, Dental Research Institute, 1983-2007 Reproductive Endocrinology Selection Committee Breast Care Center Executive Committee 1988-2007 Executive Director’s Advisory Council, 1992-1994 Clinical Chairs Council, 1994-2010 Chair, Institutional Review Committee, Gene Therapy Program Project, 1992-2007

Max Wicha, MD 8

Howard Hughes Medical Institute Dean’s Advisory Committee, 1992-2007 Strategic Planning Policy & Organizational Committee, Health Sciences Information Technology

& Networking, 1992-present Medical School Faculty Focus Group, 1993 Medical School Review Committee, 1994-1995 Molecular Immunology Program Steering Committee, 1994-1995 Center for Organogenesis Steering Committee, 1994-2010 Incentive Task Group, 1995-1996 MSP Dean’s Advisory Council, 1995-1996 MSP Executive Committee, 1995-present Mission Health Advisory Committee, 1995-1996 Internal Advisor, SPORE in Prostate Cancer, 1995-1998 President’s Task Force: Organization of the University, 1995-1996 Chair, Gene Therapy Program Task Force, 1995-1996 Chair, Medical School Dean Search Advisory Committee, 1996 Clinical Chairs Advisory Council, 1996-2010 Chair, Executive Vice President for Medical Affairs Search Committee, 1997 Member, Board of Directors, Michigan Health Corporation, 1997-2007 Member, Biological Scholars Search Committee, 1997-2002 Member, Medical School Dean Search Advisory Committee, 1998 Member, Radiation Oncology Chair Search Committee, 1998-1999 Alternate Member, Academic Program Group Research Committee, 1998-2002 Member, Task Force on Programs, Faculty Group Practice 1998-2005 Member, Bone Marrow Transplant Advisory Council, 1999-2006 Member, University of Michigan Health System Strategic Planning Steering Committee, 1999-

2000 Co-chair, Research Planning Committee, UM Health System Strategic Planning, 1999-2000 Chair, Working Group on Research, University of Michigan Self-Study for Institutional Re-

accreditation, 1999 Chair, Howard Hughes Medical Institute Dean’s Advisory Committee, 1999 Senior Advisory Committee, Head and Neck SPORE Grant, 2000 Member, H Marvin Pollard Endowed Chair Search Committee, 2001 Member, Millie Schembechler Endowed Chair Search Committee, 2001 Chair, Search Committee for Director of Pediatric Hematology/Oncology, 2006-2007 Member, Search Committee for Dean of Medical School, 2006-2007 Member, NFGC Innovations Committee, 2007-2010 Member, Search Committee for Chief of Internal Medicine, 2008 Member, North Campus Research Campus Committee, 2009-2013 Chair, Cancer Research Committee, 2016-present COMMITTEE AND ADMINISTRATIVE SERVICES – Regional and National Co-Chair, Michigan Cancer Consortium, 1997-2009 Member, Sections Committee, American Federation for Clinical Research, Midwest Section,

1986-2002

Max Wicha, MD 9

Member, Communications Committee, American Federation for Clinical Research, Midwest Section, 1986-2002

Member, American Federation for Clinical Research Awards Committee, 1986-present Member, American Society for Clinical Oncology Award Selection Committee, 1992- present Member, American Society of Hematology Committee on Publications, 1991-1993 Member, State Legislative Committee, American Association for Cancer Research, 1992-1994 Member, Michigan Society of Hematology and Oncology Member, Association of Community Cancer Centers Member, Finance Committee, American Association for Cancer Research, 1992- 2001 Member, Awards Selection Committee, American Society of Clinical Oncology, 1992- 2012 Member, Cancer Center Support Review Committee, National Cancer Institute, 1992-1995 Chairman, Parent Committee, Cancer Center Support Review Committee, National Cancer

Institute, 1993-1995 Member, Board of Directors, American Association of Cancer Institutes, 1993-1996 Member, Nominating Committee, American Association of Cancer Institutes, 1994-present Chair, Apoptosis Session, Annual Meeting of American Association of Cancer Research, March

1995 Member, NCI Affairs Committee, American Association for Cancer Research, 1995-1996 Member, NCI Cancer Centers Review Working Group, 1995-1996 Member, Science and Technology Advisory Task Force to Congresswoman Lynn Rivers, 1995-

1996 Vice President/President Elect, Association of American Cancer Institutes, July 1996-June 1997. President, Association of American Cancer Institutes, 1997-1999. Consultant, Director Search Committee, Winship Cancer Center, Emory Univ School of

Medicine, Atlanta, GA, 1996 Member, Education Committee, American Association for Cancer Research, 1997 Member, Joseph H. Burchenal/AACR Clinical Research Award Committee, 1998 Member, Michigan State Legislative Committee, American Association for Cancer Research,

1998-2000 Chair, Board of Directors, Association of American Cancer Institutes, 1999-2001 Member, Experimental Gene Therapy Subsection of Pharmacology and Experimental

Therapeutics Program Committee, American Association for Cancer Research, 2000 Member, Executive Committee, Michigan Cancer Consortium, 2000-2014 Member, Michigan Cancer Consortium, 2001-2014 Member, Joseph H. Bruchenal/AACR Prize for Translational Cancer Research Committee, 2007 Member, Dorothy P Landin/AACR Clinical Research Award Committee, 2007 Chair, AACR Science Policy and Legislative Affairs Committee, 2007 Member, AACR Tumor Biology Subcommittee, TB2, 2007 Member, AACR Nominating Committee, 2008-2010 Member, AACR Annual Meeting Program Committee, 2010 National Cancer Advisory Board, 6/2015-5/2020 BIBLIOGRAPHY

Completed Publications in Scientific Journals-Peer Reviewed Over 43,910 citations; h-index 81; i10-index 195

Max Wicha, MD 10

1. Wicha MS, Stockdale FE: DNA dependent DNA polymerases in differentiating embryonic muscle cells. Biochem Biophys Res Comm 1972; 48:1079-1087.

2. Kidwell WR, Monaco ME, Wicha MS, Smith GS: Unsaturated fatty acid requirements for growth and survival of a rat mammary tumor cell line. Cancer Research 1978; 38:426-435.

3. Wicha MS, Liotta LA, Kidwell WR: Effect of free fatty acids on the growth of normal and neoplastic rat mammary epithelial cells. Cancer Research 1979; 39:426-435.

4. Wicha MS, Liotta LA, Garbisa S, Kidwell WR: Basement membrane collagen requirements for attachment and growth of mammary epithelium. Expt Cell Res 1979; 124: 181-190.

5. Liotta LA, Wicha MS, Rennard S, Foidart J, Garbissa S, Kidwell WR: Hormonal requirements for basement membrane collagen deposition by cultured rat mammary epithelium. Lab Invest 1979; 41:511-518.

6. Wicha MS, Liotta LA, Vonderhaar BK, Kidwell WR: Effects of inhibition of basement membrane collagen deposition on rat mammary development. Developmental Biol 1980; 80:253-266.

7. Wicha MS, Liotta LA, Lewko W, Kidwell WR: Blocking basement membrane collagen deposition inhibits the growth of 7, 12-dimethylbenzanthracene induced rat mammary tumors. Cancer Letters 1981; 12:9-21.

8. Lewko WM, Liotta LA, Wicha MS, Vonderhaar BK, Kidwell WR: Sensitivity of N-Nitro-somethylurea-induced rat mammary tumors to cis-hydroxyproline an inhibitor of collagen production. Cancer Research 1981; 41:2855-2862.

9. Cowen S, Anhalt G, Wicha M, Sugar A, Sabib P, Diaz L: Distribution of pemphigus and phemphigoid antigens, laminin, and type IV collagen in corneal epithelium. Investigative Ophth 1981; 21:879-882.

10. Wicha MS, Lowrie G, Kohn E, Bagavandoss P, and Mahn T: Extracellular matrix promotes mammary epithelial growth and differentiation in vitro. Proc Natl Acad Sci USA 1982; 79:3213-3217.

11. Wicha MS: Growth and differentiation of rat mammary epithelium on mammary gland extracellular matrix. The Extracellular Matrix, S Hawkes, J Wang. (Ed.) Academic Press, New York, 1982, pp 309-314.

12. Wicha MS, and Huard TK: Macrophages express cell surface laminin. Exp Cell Res 1983; 143:475-479.

13. Bagavandoss P, Midgley R, and Wicha MS: Developmental changes in ovarian follicular basal lamina detected by immunofluorescence and electron microscopy. J Histochem and Cytochem 1983; 31:633-640.

14. Varani J, Lovett EJ, McCoy JP, Shibata S, Maddox D, Goldstein IJ, and Wicha MS: Differential expression of a laminin-like substance by high- and low-metastatic tumor cells. Amer J Path 1983; 111:27-34.

Max Wicha, MD 11

15. Zuckerman KS, and Wicha MS: Extracellular matrix production by the adherent cells of long term murine bone marrow cultures. Blood 1983; 61:540-547.

16. Virolainen E, Carey TE, Wicha M, and Krause CJ: Factors affecting the growth of head and neck squamous carcinoma cell lines. Otolaryngology: Head and Neck Surgery 1983; 91:126-135.

17. Malinoff H and Wicha MS: Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells. J Cell Biol 1983; 96:1475-1479.

18. Brown SS, Malinoff HL, and Wicha MS. Connectin, a cell surface protein that binds both laminin and actin. Proc Natl Acad Sci USA 1983; 80:5927-5930.

19. Varani J, Lovett EJ, Wicha MS, Malinoff H, and McCoy P: Cell surface a-D-galactopyranosyl end groups: use as a marker in the isolation of murine tumor cell lines with varying malignant potential. J Natl Cancer Inst 1983; 71:1281-1287.

20. McCoy Jr JP, Lloyd RV, Wicha MS, Varani J: Identification of a laminin-like substance on the surface of high-malignant murine fibrosarcoma cells. J Cell Biol 1984; 65:139-151.

21. Malinoff HL, McCoy JP, Varani J, and Wicha MS: Metastatic potential of murine fibrosarcoma cells is influenced by cell surface laminin. Int J Cancer 1984; 33:651-655.

22. Zuckerman KS, Rhodes RK, Goodrum DD, Patel VR, Sparks B, Wells J, Wicha MS, Mayo LA: Inhibition of collagen deposition in the extracellular matrix prevents the establishment of a stroma supportive of hematopoiesis in long-term murine. J Clin Invest 1985; 75:970-975.

23. Campbell AD, Wicha MS, Long M: Extracellular matrix promotes the growth and differentiation of murine hematopoietic cells in vitro. J Clin Invest 1985; 75:2085-2090.

24. Klohs WD, Steinkampf RW, Wicha MS, Mertus AE, Tunac JB, Leopold WR: Collagen-production inhibitors evaluated as antitumor agents. J Natl Cancer Inst 1985; 75:53-359.

25. Huard TK, Baney JL, Wood JF, Wicha MS: A potential role for the extracellular matrix glycoprotein laminin in macrophage-tumor cell interactions. Int J Cancer 1985; 36:511-517.

26. Huard TK, Malinoff H, Wicha MS: Macrophages express a plasma membrane receptor for basement membrane laminin. Am J Pathol 1986; 123:365-370.

27. Cody R, Wicha MS: Clustering of cell surface laminin enhances its association with the cytoskeleton. Exp Cell Res 1986; 165:107-116.

28. Yoon PS, Boxer LA, Mayo LA, Yang AY, Wicha MS: Human neutrophil laminin receptors: Activation-dependent receptor expression. J Immunology 1987; 138:259-265.

29. Campbell AD, Long MW, Wicha MS: Hemonectin, a bone marrow adhesion protein specific for cells of granulocyte lineage. Nature 1987; 329:744-746.

30. Blum JL, Zeigler ME, Wicha MS: Regulation of rat mammary gene expression by extracellular matrix components. Expt Cell Res 1987; 173:322-340.

31. Blum JL, Wicha MS: Role of the cytoskeleton in laminin induced mammary gene expression. J Cellular Physiol 1988; 135:13-22.

Max Wicha, MD 12

32. Campbell AD, Wicha MS: Extracellular matrix and the hematopoietic microenvironment. J Lab & Clin Med 1988; 112(2):140-146.

33. Hutchinson R, Fligiel S, Appleyard J, Varani J, Wicha MS: Attachment of neuroblastoma cells to extracellular matrix: Correlation with metastatic capacity. J Lab & Clin Med 1989; 113(5):561-568.

34. Ervin PR, Kaminski M, Cody R, Wicha MS: Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 1989; 244:1585-1587.

35. Pike MC, Wicha MS, Yoon P, Mayo LA, Boxer LA: Laminin promotes the oxidative burst in human neutrophils via increased chemoattractant receptor expression. J Immunology 1989; 142:2004-2011.

36. Zeigler ME, Edwards TE, Wicha MS: Isolation and sequence analysis of laminin receptor cDNA clone. J Cell Biol 1989; 107:801.

37. Blum JL, Zeigler ME, Wicha MS: Regulation of mammary differentiation by the extracellular matrix. Environ Hlth Persp 1989; 80:71-83.

38. Elder JT, Tavakkol A, Klein SB, Zeigler ME, Wicha M, Voorhees JJ: Protooncogene expression in normal and psoriatic skin. J Invest Derm 1990; 94:19-25.

39. Peter C, O’Shea KS, Campbell AD, Wicha MS, Long MW: Fetal expression of hemonectin: an extracellular matrix hematopoietic cytoadhesion molecule. Blood 1990; 75:357-364.

40. Campbell AD, Long MW, Wicha MS: Developmental regulation of granulocytic cell binding to hemonectin. Blood 1990; 76:1758-1764.

41. Campbell A, Sullenbarger B, Bahou W, Ginsburg D, Long M, Wicha M: Hemonectin: a novel hematopoietic adhesion molecule. Prog Clin Biol Res 1990; 352:97-105.

42. Anklesaria P, Greenberger JS, Fitzgerald TJ, Sullenbarger B, Wicha MS, Campbell AD: Hemonectin mediates adhesion of engrafted murine progenitors to a clonal bone marrow stromal cell line from S1/S1d mice. Blood 1991; 77:1691-1698.

43. Bignon C, Roux-Dosseto M, Zeigler ME, Mattei M, Lissitzky JC, Wicha MS, Martin P: Genomic analysis of the 67KDa laminin receptor in normal and pathological tissue: evidence for retroposon features. Genomics 1991; 10:481-485.

44. Zeigler ME, Wicha MS: Post-transcriptional regulation of -casein mRNA accumulation by laminin. Exp Cell Res 1992; 200:481-489.

45. Bahou WF, Campbell AD, Wicha MS: cDNA cloning and molecular characterization of MSE55, a novel human serum constituent protein that displays bone marrow stromal/endothelial cell-specific expression. J Biol Chem 1992; 267(20):13986-13992.

46. Bignon C, Roux-Dosseto M, Zeigler ME, Wicha MS, Martin PM: cDNA cloning and genomic analysis of new multigene family sharing common phylogenetic and expression profiles with the laminin receptor gene. BBRC 1992; 184:1165-1172.

47. McCauley DL, Calzone K and Wicha M: Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions. J Clin Oncol 1994; 12(5)1102-3.

Max Wicha, MD 13

48. Sullenbarger BA, Petitt MS, Chong SP, Long MW and Wicha MS: Murine granulocytic cell adhesion to bone marrow hemonectin is mediated by mannose and galactose. Blood 1995; 86(1)135-140.

49. Sumantran V, Ealovega MW, Nunez G, Clarke MF, and Wicha MS: Overexpression of Bcl-xS sensitizes MCF-7 cells to chemotherapy induced apoptosis. Cancer Research, 1995; 55:2507-2510.

50. Fukunaga N, Ryan JJ, Wicha M, Nunez G, Clarke MF: Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation-induced cell death. Carcinogenesis, 1995; 16(8):1761-7.

51. Clarke MF, Apel IJ, Benedict MA, Eipers PG, Sumantran V, Gonzalez-Garcia M, Doedens M, Fukunaga N, Davidson B, Dick JE, Minn AJ, Boise LH, Thompson CB, Wicha M, Nunez G: A recombinant bcl-xs adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. PNAS, 1995; 92:11024-11028.

52. Ealovega MW, McGinnis PK, Sumantran VN, Clarke MF and Wicha MS: bcl-xS gene therapy induces apoptosis of human mammary tumors in nude mice. Ca Res, 1996; 56:1965-1969.

53. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Halvie M, August D, Wicha M, Lichter A, Pierce LJ. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Onc, 1997; 15(8):2873-2881.

54. Han JS, Nunez G, Wicha MS, Clarke MF. Targeting cancer cell death with a bcl-xS adenovirus. Springer Semin Immunopathol, 1998; 19:279-288.

55. Fig LM, Brown RS, von Moll L, Appelman HD, Stevens R, Harness J, August D, Sondak V, Chang AE, Zasadny KR, Fisher SJ, Johnson JW, Wicha MS, Colcher D, Lichter AS, Wahl RL. Immunolymphoscintigraphy in breast cancer: Evaluation using 131 I-labeled monoclonal antibody B72.3. Nuc Med & Bio, 1998; 25:251-260.

56. Han JS, Qian D, Wicha MS, Clarke MF. A method of limited replication for the efficient in vivo deliver of adenovirus to cancer cells. Human Gene Therapy 1998; 9:1209-1216.

57. Sun Y, Wicha M, Leopold W. Regulation of metastasis-related gene expression by p53: A potential clinical implication. Molecular Carcinogenesis 1999; 24(1):25-28

58. Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Br Ca Res & Treatment 1999; 53(3):241-253

59. Beidler DR, Ahuja D, Wicha MS and Toogood PL. Inhibition of protein synthesis by didemnin B is not sufficient to induce apoptosis in human mammary carcinoma (MCF7) cells. Biochemical Pharmacology 1999; 58(6):1067-1074

60. Liu R, Page C, Beidler DR, Wicha MS, Nunez G. Overexpression of Bcl-xL promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. Am J Pathology 1999; 155(6):1861-1867

Max Wicha, MD 14

61. Sumantran VN, Zhang R, Lee DS, Wicha MS. Differential regulation of apoptosis in normal versus transformed mammary epithelium by Lutein and Retinoic acid. Ca Epidemiology, Biomarkers and Prevention 2000; 9(3):257-63

62. Sumantran VN, Lee DS, Woods Ignatoski KM, Ethier SP and Wicha MS. A bcl-xS adenovirus selectively induces apoptosis in transformed cells compared to normal mammary cells. Neoplasia 2000; 2(1):1-10

63. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K., Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, and Merajver SD. Treatment of metastatic cancer with Tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clinical Cancer Research 2000; 6:1-10

64. Sumantran VN, Lee DS, Baker VV, Murray S, Strawderman M, Wicha MS. A bcl-xS adenovirus demonstrates therapeutic efficacy in an ascites model of human breast cancer. J Society for Gynecologic Investigation 2000; 7(3):184-9

64. Bennett CL, Stinson TJ, Vogel V, Robertson L, Leedy D, O’Brien P, Hobbs J, Sutton T, Gesshel D, Ruckdeschel JC, Chirikos TN, Seiner RS, Ramsey MM, Wicha MS. The cost of enrolling cancer patients on Phase II clinical trials. J Clin Oncol, 2000; 18(15):2805-2810.

66. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Human Gene Therapy, 2000, 11:2009-2024.

67. Trask DK, Wolf GT, Bradford CR, Fisher SG, Devaney K, Johnson M, Singleton T, Wicha M. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: Correlation with response to chemotherapy and organ preservation. Laryngoscope 112(4): 638-644, 2002.

68. Schott, A F; Hayes, D F; Stearns, V; Wicha, M S, Baker L E. Vinorelbine (VR) and capecitabine (CAP) in metastatic breast cancer: Phase I/II study with correlative genotype, phenotype, and pharacokinetcs. Breast Cancer Research & Treatment, 76 Supplement 1:S91, December 2002

69. Dontu G, Abdallah W, Foley J, Jackson K, Kawamura M, Clarke M, Wicha M. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes and Development, 17:1253-1270, 2003.

70. Dontu G, Al-Hajj M, Abdallah W, Clarke M, Wicha M. Stem cells in normal breast development and breast cancer. Cell Proliferation, 2003, 36 (Suppl.1), 59-72.

71. Al-Hajj M, Wicha M, Morrison S, Clarke M. Prospective identification and isolation of breast cancer tumorigenic cells. PNAS, 100(7): 3983-3988, 2003.

72. Spahlinger D, Pai CW, Waldinger M, Billi J, Wicha M. New Organizational and Funds Flow Models for an Academic Cancer Center. Academic Medicine, Vol. 79, No. 7, 2004.

73. Dontu G, El-Ashry D, Wicha M. Breast cancer stem or progenitor cells and the estrogen receptor, Trends in Endocrinology and Metabolism, Vol. 15 No. 5 (193-197) 2004.

73. Al-Hajj M, Becker M, Wicha M, Weissman I, Clarke M. Therapeutic implications of cancer stem cells. Current Opinion in Genetics & Development 2004 14:43-47

Max Wicha, MD 15

74. Dontu G, Jackson K, McNicholas E, Kawamura M, Abdallah W, Wicha M. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Research, 2004, 6:R605-R615.

75. Liu S, Dontu G, Wicha M. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Research, Vol. 7, No. 3, 2005.

76. Dontu G, Wicha M. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. Journal of Mammary Gland Biology and Neoplasia, Vol. 10, No. 1, 2005.

77. Wicha M, Liu S, Dontu G. Cancer stem cells: an old idea – a paradigm shift. Cancer Research, 66:4, 2006.

78. Liu S, Dontu G, Mantle I, Patel S, Ahn N, Jackson K, Suri P, Wicha M. HedgehogSignaling and Bmi-1 regulates self-renewal of normal and malignant human mammary stem cells, Cancer Research, 66:6063-6071, 2006.

79. Wicha M. Identification of murine mammary stem cells: Implications for studies of mammary development and carcinogenesis. Breast Cancer Research, 8(5):109, 2006.

80. Wicha M. Cancer stem cells and metastasis: Lethal seeds: Commentary re: Balic M, et.al. Most of early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research, 12(19):5606-5607, 2006.

81. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Research, 67(3):1030-1037, 2007.

82. Boman BM, Wicha MS, Fields JZ, Runquist OA. Symmetric division of cancer stem cells - a key mechanism in tumor growth that should be targeted in future therapeutic approaches. Clinical Pharmacology Therapeutics, 81(6):893-898, 2007.

83. Wicha M. Breast cancer stem cells: the other side of the story. Stem Cell Review, 3(2):110-112, 2007.

84. Ashkenazi R, Jackson TL, Dontu G, Wicha MS. Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Review, 3(2):176-182, 2007.

85. Gienstier C, Wicha MS. Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Research, 9(4):109, 2007.

86. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs, 21(5):299-310, 2007.

87. Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer Journal, 13(5):271-275, 2007.

88. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1:555-567, 2007.

Max Wicha, MD 16

89. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer C, Merajver S, Dontu G, Wicha M. BRCA1 regulates human mammary stem/progenitor cell fate. Proceeding of the National Academy of Science, 105:1680-1685, 2008.

90. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. Editorial. Breast Cancer Research, 10:105, 2008. PMCID: PMC2397532

91. Korkaya H, Paulson A, Iovino F, Wicha M. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene, 27:6120-6130, 2008. PMCID: PMC2602947

92. Kakarala M, Wicha MS. Implications of the cancer stem cell hypothesis for breast cancer prevention and therapy. JCO, 26:2813-2820, 2008. PMCID: PMC2789399

93. Huang EH, Wicha MS: Colon cancer stem cells: Implications for prevention and therapy. Trends in molecular medicine,14:503-509, 2008. PMCID: PMC2789402

94. Eliane JP, Repollet M, Luker KE, Brown M, Rae JM, Dontu G, Schott AF, Wicha M, Doyle GV, Hayes DF, Luker GD. Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Research, 68:5529-5532, 2008. PMCID: PMC2789403

95. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast : current opinion and future challenges. Pathobiology, 75:75-84, 2008. PMCID: PMC2789397

96. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Research, 69:466-474, 2009. PMCID: PMC3039129

97. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 15;69(8):3382-9, 2009. PMCID: PMC2789401

98. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G, Wicha MS. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Research and Treatment, 122:777-85, 2009. PMCID: PMC3039120

99. Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, Brown M, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/β-Catenin signaling. PLoS Biol 7(6): e1000121. doi:10.1371/journal.pbio.1000121, 2009. PMCID: PMC2683567

100. Wicha MS. Targeting breast cancer stem cells. The Breast, S: 56-58, 2009.

101. Gur D, Liu S, Wicha M, Shukla A, Krag D. Identification of single chain antibodies to breast cancer stem cells using phage display. Biotechnology Progress; 25:1780-1787, 2009.

102. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clinical Cancer Research; 15:6386-6390. PMCID: PMC2787085

103. Ginestier C, Liu S, Wicha MS. Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell; 5:229-230, 2009.

Max Wicha, MD 17

104. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS, Birnbaum D, Charafe-Jauffret E. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle; 8:3297-3302, 2009. PMCID: PMC2861502

105. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res; 69: 1302-1313, 2009. PMCID: PMC2819227

106. Charafe-Jauffret E, Ginestier C, Iovino F., Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, Xerri L, Dontu G, Stassi G, Xiao Y, Barsky S, Birnbaum D, Viens P, Wicha M.S. Aldehyde Dehydrogenase 1-Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer. Clinical Cancer Research; 16:45, 2010. PMCID: PMC2874875

107. Ginestier C, Liu S, Diebel M, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation: doi: 10.1172/JCI139397, 2010. PMCID: PMC2810075

108. Liu S and Wicha MS. Targeting breast cancer stem cells. Journal of Clinical Oncology: Journal of Clinical Oncology, 28:4006-12, 2010.

109. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS and Prince ME. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 32:1195-201, 2010. PMCID: PMC2991066

110. Kakarala M, Brenner DE, Korkaya H, Cheng C, Tazi K, Ginestier C, Liu S, Dontu G and Wicha MS. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Research and Treatment, 122:777-85, 2010. PMCID: PMC3039120

111. Li Y, Zhang T, Korkaya H, Liu S, Lee HF, Newman B, Yu Y, Clothier SG, Schwartz SJ, Wicha MS and Sun D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clinical Cancer Research, 16:2580-90, 2010. PMCID: PMC2862133

112. McDermott SP and Wicha MS. Targeting breast cancer stem cells. Molecular Oncology, 4:404-19, 2010. PMCID: PMC3023958

113. McDermott SP and Wicha MS. Breast tumors: of mice and women. Breast Cancer Research, 12:108, 2010. PMCID: PMC2917013

114. Stark A, Kleer CG, Martin I, Awuah B, Nsiah-Asare A, Takyi V, Braman ME, Quayson S, Zarbo R, Wicha M and Newman L. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer. Jul 13, epub ahead of print, 2010. PMCID: PMC3138711

115. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS and Nor JE. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 70:9969-78, 2010. PMCID: PMC3058885

Max Wicha, MD 18

116. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R and Wicha MS. Breast cancer stem cells are regulated by mesenchumal stem cells through cytokine networks. Cancer Research, 71:614-24, 2011. PMCID: PMC3100554

117. Li Y, Wicha MS, Schwarts SJ and Sun D. Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. Journal of Nutritional Biochemistry, 22:799-806, 2011. PMCID: PMC3248810

118. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R and Zou W. Expression of aldhehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International Journal of Cancer, 130:29-39, 2011. PMCID: PMC3164893

119. Silva IA, Bai S, McLean K, Yang K, Griffith KA, Dafydd T, Ginestier C, Johnston C, Kueck A, Reynolds K, Wicha MS and Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Research, 71:3991-4001, 2011. PMCID: PMC3107359

120. Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP and Yang ZQ. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene, 31:333-341, 2011.

121. Korkaya H, Liu S and Wicha MS. Regulation of cancer stem cells by cytokine networks: Attaching cancers inflammatory roots. Clinical Cancer Research, 17:6125-6129, 2011. PMCID: PMC3312242

122. Zielske SP, Spalding AC, Wicha MS and Lawrence TS. Ablation of breast cancer stem cells with radiation. Translational Oncology, 4:217-23, 2011. PMCID: PMC3140010

123. Korkaya H, Liu S and Wicha MS. Breast cancer stem cells, cytokine networks and the tumor microenvironment. Journal of Clinical Investigation, 121:3804-09, 2011. PMCID: PMC3223613

124. Conley SJ , Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN , Clouthier SG, Wicha MS. Anti-angiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA, 109(8):2784-9, 2012. PMCID: PMC3286974

125. Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, McDermott S, Shang L, Ke J, Sing OJ, Heath A, Zhang KJ, Korkaya H, Clouthier SG, Charafe-Jauffret E, Birnbaum D, Hannon GJ, Wicha MS. microRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genetics, 8(6): e1002751. doi:10.1371/journal/pgen.1002751, 2012. PMCID: PMC3369932

126. Liu S, Clouthier SG, Wicha MS. Role of microRNAs in the regulation of breast cancer stem cells. Journal of Mammary Gland Biology Neoplasia, 17:15-21, 2012.

127. Korkaya H, Kim G, Davis A, Malik F, Quraishi AA, Henry NL, Ithimakin S, Tawakkol N, D’Angelo R, Paulson A, Chung S, Luther T, Paholak HS, Liu S, Hassan K, Zen Q, Clouthier SG, Wicha MS. Activation of an IL-6 inflammatory loop mediates trastuzumab resistance in HER2 overexpressing breast cancers by expanding the cancer stem cell population. Molecular Cell, 47:570-584, 2012.

Max Wicha, MD 19

128. Malik F, Korkaya H, Clouthier SG, Wicha MS. Lin28 and HER2: Two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle, 11:2780-81, 2012.

129. Conley JS, Wicha MS. Antiangiogenic agents, fueling cancer’s hypoxic roots. Cell Cycle, 11:1265-66, 2012. PMCID: PMC3432419

130. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, Banerjee M, Mao Y, Kotarski J, Wicha MS, Liu R, Zou W. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International Journal of Cancer, 130:29-39, 2012. PMCID: PMC3419057

131. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince MEP, Xu Y, Zhang X, Huang S, Chang AE, Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Research, 72:1853-1864, 2012. PMCID: PMC3320735

132. Duru N, Fan M, Candas D, Menaa C, Liu H, Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, Li S, Spitz DR, Lam KS, Wicha MS, Li JJ. HER2-associated radiation resistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clinical Cancer Research, 18:6634-47, 2012. PMCID: PMC3593096

133. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab. Cancer Research, 73:1635-46, 2013. PMCID: PMC3600586

134. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, Kalemkerian GP, Wicha MS. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clinical Cancer Research, 19:1972-80, 2013. PMCID: PMC3630232

135. Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froelich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clinical Cancer Research, 19:1512-24, 2013. PMCID:PMC3602220

136. Luo M, Zhao X, Chen S, Liu S, Wihca MS, Guan JL. Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res; 73(17); 1–12, 2013.

137. Schwartz, T., Stark, A., Pang, J., Awuah, B., Kleer, C. G., Quayson, S., Kingman, S., Aitpillah, F., Abantanga, F., Jiagge, E., Oppong, J. K., Osei-Bonsu, E., Martin, I., Yan, X., Toy, K., Adjei, E., Wicha, M. and Newman, L. A., Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer, 119: 488–494, 2013. doi: 10.1002/cncr.27737

138. Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, Wicha MS, Chang AE, Li Q. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo. Clinical Immunology, 149:156-168, 2013.

Max Wicha, MD 20

139. Vu-Phan D, Grachtchouk V, Yu J, Colby LA, Wicha MS, Koenig RJ. The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocrinology, 20(5):725-739, 2013.

140. Cui TX, Kryczek I, Shao L,Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DF, Kotarski J, Tarkowski R, Wicha MS, Cho K, Giordano T. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity, 39:1-11, 2013 http://dx.doi.org/10.1016/j.immuni.2013.08.025

141. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, Lin J, Ramnath N, Wicha MS, Hayes DF, Simeone DM, Nagrath S. Sensitive capture of circulating tumour cells by functionalized grapheme oxide nanosheets. Nature Nanotechnology, 8(10):735-741, 2013.

142. Lin L, Hutzen B, Lee H, Peng Z, Lin H, Sun D, Li P, Li C, Korkaya H, Wicha MS, Lin J. Evaluation of STAT3 signaling in ALDH+ and ALDH+/CD44+/CD24- subpopulations of breast cancer cells. PLoS One, 8(12): e82821, 2013.

143. Wang SH, Lu L, Fan Y, Wicha MS, Cao Z, Chang AE, Xia J, Baker JR, Li Q. Characterization of a novel transgenic mouse tumor model for targeting HER2 cancer stem cells. International Journal of Biological Sciences, 10(1):25-32, 2013.

144. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnaum D, Wong ST, Zhan M, Chang JC, Wicha MS. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports, 2:78-91, 2014.

145. Li Q, Lu L, Tao H, Xue C, Teitz-Tennenbaum S, Owen JH, Moyer JS, Prince ME, Chang AE, Wicha MS. Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells. J. Vis. Exp. (83), e50561, doi:10.3791/50561, 2014.

146. Lombardi S, Honeth G, Ginestier C, Shinomiya I, Marlow R, Buchupalli B, Gazinska P, Brown J, Catchpole S, Liu S, Barkan A, Wicha M, Purushotham A, Burchell J, Pinder S, Dontu G. Growth hormone is secreted by normal breast epithelium upon progesterone stimulation and increases proliferation of stem/progenitor cells. Stem Cell Reports, 2:780-93, 2014.

147. Murlidhar V, Zeinali M, Grabauskiene S, Ghannad-Rezaie M, Wicha MS, Simeone DM, Ramnath N, Reddy RM, Nagrath S. A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small; DOI:10.1002/smll.201400719, 2014.

148. Deng L, Shang L, Bai, S, Chen J, He X, Martin-Trevino R, Chen S, Li X, Meng X, Yu B, Wang X, Liu Y, McDermott SP, Ariazi AE, Ginestier C, Ibarra I, Ke J, Luther T, Clouthier SG, Xu L, Shan G, Song E, Yao H, Hannon GJ, Weiss ST, Wicha MS, Liu S. microRNA100 inhibits breast cancer stem cells self-renewal and tumor development. Cancer Res, doi: 10.1158/0008-5472.CAN-13-3710

149. Krishnamurthy S, Warner KA, Dong Z, Imai A, Nor C, Ward BB, Helman JI, Taichman RS, Bellile EL, McCauley LK, Polverini PJ, Prince ME, Wicha MS, Nor JE. Endothelial

Max Wicha, MD 21

interleukin-6 degines the tumorigenic potential of primary human cancer stem cells. Stem Cells, 32:2845-2857, 2014.

150. Zhang Z., Shiratsuchi H., Lin J., Chen G., Reddy R., Azizi E., Fouladdel S., Chang A., Lin L., Jiang H., Waghray M., Luker G., Simeone D., Wicha MS., Beer D., Ramnath N., Nagrath S. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget, 5, 2014.

151. Lu Deng, Li Shang, Shoumin Bai, Ji Chen, Xueyan He, Rachel Martin-Trevino, Shanshan Chen, Xiao-yan Li, Xiaojie Meng, Bin Yu, Xiaolin Wang, Yajing Liu, Sean P. McDermott2, Alexa E. Ariazi, Christophe Ginestier, Ingrid Ibarra, Jia Ke, Tahra Luther, Shawn G. Clouthier, Liang Xu, Ge Shan,Erwei Song, Herui Yao, Gregory J. Hannon, Stephen J. Weiss, Max S. Wicha, and Suling Liu. MicroRNA100 Inbhibts Self-Renewal of Breast Cancer Stem-like Cells and Breast Tumor Development. Cancer Research, 74(22), November, 15, 2014.

152. Liu S, Yin F, Zhang J, Wicha MS, Chang AE, Fan W, Chen L, Fan M, Li Q. Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. Journal of Cell Biochemistry, 115:1368-1380, 2014.

153. Ke J, Zhao Z, Hong S, Bai S, He Z, Malik F, Xu J, Zhou L, Chen W, Martin-Trevino R, Wu X, Lan P, Yi Y, Ginestier C., Ibarra I, Shang L, McDermott S, Luther T, Clouthier S, Wicha M, & Liu S. Role of MicroRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells. Oncotarget, 5, 2015.

154. D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, Kim G, Luther T, Quraishi AA, Senbabaoglu Y, Conley SJ, Clouthier SG, Hassan KA, Wicha MS, Korkaya H. Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity. Molecular Cancer Therapeutics, doi:10.1158/1535-7163.MCT-14-0228, 2015.

155. Liu Y, Chen C, Qian P, Lu X, Sun B, Zhang X, Wang L, Gao X, Li H, Chen Z, Tang J, Zhang W, Dong J, Bai R, Lobie PE, Wu Q, Liu S, Zhang H, Zhao F, Wicha MS, Zhu T, Zhao Y. Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nature Communications, 6:5988, 2015.

156. Luo M, Brooks M, Wicha MS: Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Current Pharmaceutical Design, 21:1301-1310, 2015.

157. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, Wicha MS, Korkaya H. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. Oncogene, 34:671-680, 2015.

158. Conley SJ, Baker TL, Burnett JP, Thiesen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS. CRLX101, an investigational camptothecin-contining nanoparticle-ddrug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Research and Treatment, 150:559-567, 2015.

159. Lu L, Tao H, Chang AE, Shu G, Chen Q, Egenti M, Owen J, Moyer JS, Prince MEP, Xia J, Huang S, Wicha, MS, Li Q. Cancer stem cell vaccine inhibits metastases of primary tumors

Max Wicha, MD 22

and induces humoral immune responses against cancer stem cells. OncoImmunology, 4:3, e990767, DOI: 10.4161/2162402X.2014.990767, 2015.

160. Zou W and Wicha MS. Chemokines and cellular plasticity of ovarian cancer stem cells. Oncoscience, 2(7):615, 2015.

161. Zhou L, Lu L, Wicha M, Chang A, Xia J, Ren X, Li Q. Promise of cancer stem cell vaccine. Human Vaccines & Immunotherapeutics, 11(12): 2796-2799, 2015.

162. Esper R, Dame M, McClintock S, Holt P, Dannenberg A, Wicha M, Brenner D. Leptin and Adiponectin Modulate the Self-renewal of Normal Human Breast Epithelial Stem Cells. Cancer Prevention Research, 8(12):1174-1183, 2015.

163. Proctor W, Kidwell K, Jiagge E, Bensenhaver J, Awuah B, Gyan K, Toy K, Kwaku Oppong J, Kyei I, Aitpillah F, Osei-Bonsu E, Adjei E, Ohene-Yeboah M, Newman Brewer R, Ahenkorah Fondjo L, Owusu-Afriyie O, Wicha M, Merajver S, Kleer C, Newman L. Characterizing breast cancer in a population with increased prevalence of triple-negative breast cancer: androgen receptor and ALDH1 expression in Ghanaian women. Annals of surgical oncology, 22(12): 383-3835, 2015.

164. Adams A, Warner K, Pearson A, Zhang Z, Kim H, Mochizuki D, Basura G, Helman J, Mantesso A, Castilho R, Wicha M, Nör J. ALDH/CD44 identifies uniquely tumorigenic cancer stem cells in salivary gland mucoepidermoid carcinomas, Oncotarget, 6(29), 2015 Sept 9.

165. Sehl ME, Shimada M, Landeros A, Lange K, Wicha MS. Modeling of cancer stem cells state transitions predicts therapeutic response. PLoS One, 10(9), 2015 Sep 23.

166. Yao H, Gao M, Ma J, Zhang M, Li S, Wu B, Nie X, Jiao J, Zhao H, Wang S, Yang Y, Zhang Y, Sun Y, Wicha M, Chang A, Gao S, Li Q, Xu R. Transdifferentiation-Induced Neural Stem Cells Promote Recovery of Middle Cerebral Artery Stroke Rats. PloS one, 10(9), 2015.

167. Brooks MD, Burness ML, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell, http://dx.doi.org/10.1016/j.stem.2015.08.014, 2015.

168. Jack R, Grafton M, Rodrigues D, Giraldez M,Griffith C, Cieslak R, Zenali M, Kumar-Sinha C, Azizi E, Wicha M, Tewari M, Simeone D, and Nagrath S. Ultra-Specific Isolation of Circulating Tumor Cells Enables Rare-Cell RNA Profiling. Advanced Science, DOI: 10.1002/advs.201600063, 2016.

169. Hsu E, Kulp S, Huang H, Tu H, Chao M, Tseng Y, Yang M, Salunke S, Sullivan N, Chen W, Zhang J, Teng C, Fu W, Sun D, Wicha M, Shapiro C, Chen C. Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis, 37(4) pp 430-442, April 1, 2016.

170. Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, Burness ML, Azizi E, Simeone D, Wicha MS, Kim J, Nagrath S. Tunable Thermal‐Sensitive Polymer–Graphene Oxide Composite for Efficient Capture and Release of Viable Circulating Tumor CellsAdvanced Materials, DOI:10.1002/adma.201600658, April 26, 2016.

Max Wicha, MD 23

171. Finkel K, Warner, Kerk S, Bradford C, McLean S, Prince M, Zhong H, Hurt E, Hollingsworth R, Wicha M, Tice D, Nör J. IL-6 Inhibition with MEDI5117 Decreases the Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. Neoplasia, 18(5) pp 273-281, May 31, 2016.

172. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanisławek A, Polkowski W, Kurylcio A, Kleer C, Chang A, Wicha M, Sabel M, Zou W, Kryczek I. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 76 (11) pp 3156-3165, June 1, 2016.

173. Murthy P, Kidwell K, Schott A, Merajver S, Griggs J, Smerage J, Van Poznak C, Wicha M, Hayes D, Henry N. Clinical predictors of long-term survival in HER2-Positive metastatic breast cancer. Breast Cancer Research and Treatment, 155(3) pp 589-595, 2016.

174. Colacino JA, McDermott SP, Sartor MA, Wicha MS, Rozek LS. Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention. Breast Cancer Research and Treatment, pp 1-13, June 15, 2016.

175. Chen Y, Zhang Z, Fouladdel S, Deol Y, Ingram P, McDermott S, Azizi E, Wicha M, and Yoon E. Single Cell Dual Adherent-Suspension Co-Culture Micro-Environment for Studying Tumor-Stormal Interactions with Functionally Selected Cancer Stem-like Cells. Lab Chip, 16, 2935-2945, 2016.

176. Chen Y, Ingram P, Fouladdel S, McDermott S, Azizi, E, Wicha M, Yoon E. High-Throughput Single-Cell Derived Sphere Formation for Cancer Stem-Like Cell Identification and Analysis. Scientific Reports, 6, 27301. 2016. Epub 2016 June 13. Doi:10.1038/srep27301. PMID: 27292795; PMCID: PMC4904376

177. Sun L, Burnett J, Gasparyan M, Xu F, Jiang H, Lin C, Myers I, Korkaya H, Liu Y, Connarn J, He H, Zhang N, Wicha M, Sun D. Novel Cancer Stem Cell Targets during Epithelial to Mesenchymal Transition in PTEN-deficient Trastuzumab-resistant. Breast Cancer. Oncotarget, DOI: 10.18632/oncotarget.9839, 2016.

178. Paholak H, Stevers N, Chen H, Burnett J, He M, Korkaya H, McDermott S, Deol Y, Clouthier S, Luther T, Li Q, Wicha MS, Sun, D. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated phototermal therapy. Biomaterials, 104:145-57, 2016 June 23. DOI: 10.1016/j.biomaterials.2016.06.045

179. Hu Y, Lu L, Xia Y, Chen X, Chang A, Hollingsworth R, Hurt E, Owen J, Moyer J, Prince M, Dai F, Bao Y, Wang Y, Whitfield J, Xia J, Huang S, Wicha M, Li Q. Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Research, 76(16): 4661-72, 2016 August 15. DOI: 10.1158/0008-5472.CAN-15-2664.

180. Prince M, Zhou L, Moyera J, Tao H, Lua L, Owen J, Etigena M, Zheng F, Chang A, Xia J, Wolf G, Max S Wicha, Huang S, Ren X, Li Q. Evaluation of the immunogenicity of ALDH high human head and neck squamous cell carcinoma cancer stem cells in vitro. Oral Oncology, 59:30-42, 2016 August. DOI: 10.1016/j.oraloncology.2016.05.013.

Max Wicha, MD 24

181. Liu Y, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks MD, Shang L, Fox A, Luther TK, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha MS, Liu S. RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer; Clinical Cancer Research. 2017 Jan 15;23(2):514-522. doi: 10.1158/1078-0432.CCR-15-1348. Epub 2016 Dec 29. PMID: 28034904

182. Tan Z, Nie S, McDermott SP, Wicha MS, Lubman DM; Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res. 2017 Feb3; 16(2):842-851. Doi:10.1021/acs.jproteome.6b00824. Epub 2017 Jan 20; PMID: 28076950

183. Jack RM, Hussain, K, Rodrigues D, Azizi, E, Wicha MS, Simeone D, Nagrath S. Microfluidic Continuum Sorting of Sub-Populations of Tumor Cells via Surface Antibody Expression Levels; Lab Chip, 2017 Mar 29, DOI: 10.1039/C6LC01496H. PMID: 28294230

184. Zou W, Nagarsheth N, Wicha M. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy; Nature Reviews Immunology - May 2017, doi:10.1038/nri.2017.49; PMID: 28555670; PMCID: PMC5731833

185. Wadehra M, Kiyohara M, Dillard C, Kim S, Lu J, Sachdev D, Goodglick L, Tao M, Torous V, Wang W, Gordon L, Braun J, McDermott S, Wicha M, Aryasomayajula C, Najafzadeh P, Tsui J, EMP2 is a novel therapeutic target for endometrial cancer cells; Oncogene - doi: 10.1038/onc2017.142; PMID: 28604744. PMCID: PMC5648618

186. Chen YC, Baac HW, Lee KT, Gouladdel S, Teichert k, Ok JG, Cheng YH, Ingram PM, Hart AJ, Azizi E, Guo LJ, Wicha MS, Yoon E. Selective Photomechanical Detachment and Retrieval of Divided Sister Cells from Enclosed Microfluidics for Downstream Analyses. ACS Nano. 2017 May 23; 11(5):4660-4668. Doi: 10.1021/acsnano.7b00413. Epub 2017 May 8. PMID: 28480715

187. Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. Cancer Lett. 2017 May 28;394:52-64. Doi: 10.1016/j.canlet.2017.02.023. Epub 2017 Feb. 27 PMID: 28254410

188. Kolev VN, Tam WF, Wright Q, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha M, Pachter JA, Weaver DT, Inhibition of FAK kinase activity preferentially targets cancer stem cells; Oncotarget - doi: 10.1863/oncotarget.18517; June 2017; PMID: 28881682; PMCID: PMC5584283.

189. Schott AF, Goldstein L, Cristofanilli M, Wicha MS, Phase 1b pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC); Clinical Cancer Research; 2017 May; doi:10.1158/1078-0432.CCR-16-2748. PMID: 28539464; PMICD: PMC5600824

190. Nagrath S, Murlidhar V, Reddy R, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, Zhang Z, Lin J, Chang AC, Carrott PW Jr, Lynch WR, Orringer MB, Kumar-Sinha C, Palanisamy N, Beer DG, Wicha MS, Ramnath N, Azizi E, Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early Stage Lung Cancer; Cancer Research - DOI: 10.1158/0008-5472.CAN-16-2072; 17 July 2017

Max Wicha, MD 25

191. Zhang XF, Weng DSH, Pan K, Zhou ZQ, Pan QZ, Zhao JJ, Tang Y, Jiang SS, Chen CL, Li YQ, Zhang HX, Chang AE, Wicha MS, Zeng YX, Li Q, Xia JC, Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells; Molecular Carcinogenesis – 16 June 2017 doi/10.1002/mc.22697

192. Lin E*, Rivera-Báez L*, Fouladdel, S*, Yoon H, Guthrie S, Wieger J, Deol Y, Keller E, Sahai B, Simeone D, Burness ML, Azizi E, Wicha M, Nagrath S; High Throughput Microfluidic Labyrinth for the Label Free Isolation of CTCs for Single Cell Gene Expression Profiling; Cell Systems, 2017 September 20; DOI: DOI:10.1016/j.cels.2017.08.12 *these authors contributed equally

193. Wang D, Zu J, Liu B, He X, Zhou L, Hu X, Qiao F, Zhang, A, Xu X, Zhang H, Wicha M, Zhang L, Shao Z, Liu S, IL6 blockade potentiates the anti-tumor effects of y–secretase inhibitors in Notch3-expressing breast cancer; Cell Death and Differentiation, 13 October 2017 DOI: 10.1038/cdd.2017.162 PMID: 29027990

194. Ronquist S, Patterson G, Muir LA, Lindsly S, Chen H, Brown M, Wicha MS, Bloch A, Brockett R, Rajapakse I; Algorithm for cellular reprogramming; Proceedings of the National Academy of Sciences; 2017 November 7, vol. 114 no. 46; doi: 10.1073/pnas.1712350114

195. Halperin RF, Carpten JD, Manojilovic Z, Aldrich J, Keats J, Byron S, Liang WS, Russell M, Enriquez D, Claasen A, Chemi I, Awuah B, Oppong J, Wicha MS, Newman LA, Jaigge E, Kim S, Craig DW; A method to reduce ancestry related germline false positives in tumor only somatic variant calling. BMC Genomics. 2017 Oct 19: 10(1):61. doi: 10.1186/s12920-017-0296-8. PMID 29052513; PMCID5649057

196. Lin H, Hurt EM, Zhao L, Szeliga W, Harms P, Vats P, Lao C, Wicha MS, Mandai M, Zou W, Wei S, Green MD, Vatan L, Herbst R, Fecher L, Chinnaiyan AM, Lawrence T, Hamanishi J, Kryczek I; Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. Journal of Clinical Investigation, January 2018. doi: 10.1172/JCI96113

197. Sehl ME, Wicha MS; (2018) Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. In: von Stechow L. (eds) Cancer Systems Biology. Methods in Molecular Biology, vol 1711. Humana Press, New York, NY. doi: 10.1007/978-1-4939-7493-1_16. PMID: 29344897

198. Dame MK, Attili D, McClintock SD, Dedhia PH, Ouilette P, Hardt O, Chin, AM, Xue X, Laliberte J, Katz EL, Newsome GM, Hill DR, Miller AJ, Tsai Y, Agorku D, Altheim CH, Bosio A, Simon B, Samuelson L, Stoerker JA, Appelman HD, Varani J, Wicha MS, Brenner DE, Shah YM, Spence JR, Colacino JA; Identification, Isolation, and Characterization of Human LGR5-positive Colon Adenoma Cells. Development (Publication in Process

Non-Peer Reviewed

1. Expert Consultations in Breast Cancer: Critical Pathways and Clinical Decision Making. Hait WN, August DA, Haffty BG (eds). Marcel Dekker, New York, 1999

Max Wicha, MD 26

2. Boman BW, Wicha MS. Cancer stem cells: A step toward the cure. JCO, 26:2795-2799, 2008.

3. Lewis MT and Wicha MS. Tumor-initiating cells and treatment resistance: How goes the war? Journal of Mammary Gland Biology and Neoplasia, 14:1-2, 2009.

4. Korkaya H and Wicha MS. HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil. Clinical Cancer Research, 15(6):1845-1847, 2009.

5. Wicha MS. Development of ‘synthetic lethal’ strategies to target BRCA1-deficient breast cancer. Breast Cancer Research; 11:108, 2009.

6. Korkaya H and Wicha MS. Cancer stem cells: nature vs nurture. Nature Cell Biology; 12(5):419-21, 2010.

7. Iniesta MD, Chien J, Wicha M and Merajver SD. One-hit effects and cancer. Cancer Prevention Research, 3:12-5, 2010.

8. Wicha MS. Stemming a tumor with little miR. Nature Medicine, 17:162-64, 2011.

9. Wicha MS and Hayes DF. Circulating tumor cells: Not all detected cells are bad and not all bad cells are detected. Journal of Clinical Oncology, 29:1508-11, 2011.

10. Korkaya H and Wicha MS. Inflammation and autophagy conspire to promote tumor growth. Cell Cycle, 10:2623-24, 2011.

11. Wicha, MS. PSA Lo and Behold: Prostate Cancer Stem Cells. Cell Stem Cell, 10:482-83, 2012.

12. Wicha MS. Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame? Breast Cancer Research, 14:114, 2012.

13. Wicha, MS. B4 Androgen ablation: Attacking the prostate cancer stem cell. Journal of Clinical Investigation, 123:563-65, 2013.

14. Korkaya H and Wicha MS. Breast Cancer Stem Cells: We’ve got them surrounded. Clinical Cancer Research, 19:511-13, 2013.

15. Azizi E and Wicha MS. Point: Cancer stem cells- The evidence accumulates. Clinical Chemistry, 59:205-07, 2013.

16. Korkaya H and Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Research; 73(12); 3489–93, 2013.

17. Wicha MS. Targeting self-renewal, the Achilles heel of cancer stem cells. Nature Medicine; 20(1); 29-36, 2014.

18. Fearon ER and Wicha MS. KRAS and cancer stem cells in APC-mutant colorectal cancer. Journal of the National Cancer Institute; 106:doi:10.1093/jnci/djt444, 2014.

19. Azizi E, Clouthier SG, Wicha MS. The promise of single cell omics for onco-therapy. J Mol Genet Med, 8:3 http://dx.doi.org/10.4172/1747-0862.1000121, 2014

Max Wicha, MD 27

20. Luo M and Wicha MS. Metabolic plasticity of cancer stem cells. Oncotarget, Advance Publications, DOI: 10.18632/oncotarget.6177, 2015.

21. Luther T, Jiagge E, Lewis M, Monsma D, Webb C, Liu S, Korkaya H, McDermott S, Clouthier S, Newman L, Thomas D, Wicha M. Creating a comprehensive patient-derived xenograft (PDX) bank to represent racial disparities in triple-negative breast cancer(TNBC). Cancer Epidemiology Biomarkers & Prevention, 24(10):PR09, 2015.

22. Paholak H, Stevers N, Burnett J, Chen H, McDermott S, He M, Luther T, Clouthier S, Wicha M, Sun D. Epithelial-like breast cancer stem cells are preferentially sensitive to nanoparticle-mediated hyperthermia. Cancer Research, 75(15): 4239, 2015.

23. Hernandez-Aya L, Liu Y, Kerr K, Tamura S, Neamati N, Wicha M, Burness M. Targeting the gp130 receptor in preclinical models of triple-negative breast cancer. Cancer Research, 75(15):4454, 2015.

24. Lin E, Rivera L, Yoon H, Fouladdel S, Wieger J, Guthrie S, Deol Y, Clouthier S, Luther T, Simeone D, Burness M, Azizi E, Wicha M, Nagrath S. Label-free high throughput microfluidic device for the isolation of circulating tumor cells from breast cancer patients. Cancer Research, 75(15):1593, 2015.

25. Jiagge E, Wong S, Lupu G, Qiao M, Dziubinski M, Newman L, Carpten J, Wicha M, Merajver S. Prevalent loss of BRCA1 and BRCA2 expression in African TNBC suggests their prominent role in sporadic carcinogenesis. Cancer Research, 75(15):3852, 2015.

26. Murlidhar V, Reddy R, Azizi E, Zhao L, Grabauskiene S, Zhang Z, Ramnath N, Lin J, Chang A, Carrott P, Lynch W, Orringer M, Wicha M, Palanisamy N, Beer D, Nagrath S. A study of pulmonary and peripheral vein blood as sources of circulating tumor cells in early lung cancer. Cancer Research, 75(15):1581, 2015.

27. Wicha, M. Breast cancer stem cell state transitions mediate therapeutic resistance. Cancer Research, 75(15): SY27-03-SY27-03, 2015.

28. Prince M, Zhou L, Xia Y, Tao H, Moyer J, Lu L, Owen J, Chang A, Xia J, Wolf G, Wicha M, Ren X, Bao Y, Huang S, Li Q. Evaluation of the immunogenicity of ALDHhigh human head and neck squamous cell carcinoma cancer stem cells in vitro. Cancer Research, 75(15): 1410, 2015.

29. Fouladdel S, Yoon H, Lin E, Hyun Kim T, Deol Y, Luther T, Clouthier S, Jiang H, Burness M, Nagrath S, Azizi E, Wicha M. Gene expression signatures of isolated circulating tumor cells from metastatic breast cancer patients reveal presence of breast cancer stem cells with EMT or MET phenotypes. Cancer Research, 75(15):4726, 2015.

30. Hu Y, Lu L, Chang A, Egenti M, Owen J, Moyer J, Prince M, Xia J, Huang S, Wicha M, Li Q. Therapeutic efficacy of cancer stem cell vaccine in an adjuvant setting, 75(15):1530, 2015.

31. Jiagge E, Song Q, Wong S, Luther T, Dziubinski M, Clouthier S, McDermott S, Newman L, Carpten J, Li J, Wicha M, Merajver S. Multiethnic triple negative breast cancer comparisons of gene expression shows enrichment of distinct pathways in ALDH1+ subpopulations compared to CD44+/CD24-/EpCAM+. Cancer Research, 75(15):1518, 2015.

Max Wicha, MD 28

32. Deol Y, McDermott S, Lubman D, Chang J, Nie S, Luther T, Cong Y, Azizi E, Colacino J, Clouthier S, Wicha M. Annexin A3 regulates MET-like aldehyde dehydrogenase positive breast cancer stem cells. Cancer Research, 75(15):2220, 2015.

33. Azizi E, Jiagge E, Fouladdel S, Wong S, Dziubinski M, Sehl M, Kyani A, Li J, Jiang H, Luther T, Clouthier S, McDermott S, Carpten J, Newman L, Merajver S, Wicha M. Single cell multiplex gene expression analysis to unravel heterogeneity of PDX samples established from tumors of breast cancer patients with different ethnicity. Cancer Research, 75(15): 4834, 2015.

34. Esper R, Dame M, McClintock S, Simon B, Wicha M, Brenner D. Leptin drives mammary stem cell self-renewal via the mTOR pathway. Cancer Research, 75(15):1509, 2015.

35. Zeinali M, Murlidhar V, Fouladdel S, Hafner M, Shao S, Azizi E, Wicha M, Cuneo K, Simeone D, Nagrath S. Analysis of circulating epithelial and EMT-like CTCs in pancreatic cancer using a sensitive microfluidic CTC capture device. Cancer Research, 75(15):1595, 2015.

36. Liu Y, Martin-Trevino R, Shang L, Davis A, Wicha M, Liu S, Burness M. Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer. Cancer Research, 75(15):4226, 2015.

37. Yoon H, Shanker A, Wang Y, Kozminsky M, Fouladdel S, Burness M, Azizi E, Wicha M, Kim J, Nagrath S. Capture and release of circulating tumor cells by temperature-sensitive graphene oxide-polymer composite. Cancer Research, 75(15):279, 2015.

38. Ouzounova M, Lee E, Novakovic E, Kumar Noonepalle S, Piranlioglu R, Shi H, Wicha M, Korkaya H. SOCS3 regulates IDO proteasomal degradation and inflammatory signaling in triple negative breast cancer. Cancer Research, 75(15):1984, 2015.

39. Korkaya H, Lee E, Ouzounova M, El Andaloussi A, Novakovic E, Piranlioglu R, Demirci M, Clouthier S, Wicha M. Systemic early immune priming via tumor-secreted cytokines facilitates breast cancer metastasis in syngeneic mouse model. Cancer Research, 75(15):466, 2015.

40. Brooks M and Wicha M. Quantification of dedifferentiation rates in breast cancer using fluorescent reporter constructs and lineage tracing. Cancer Research, 75(15):1504, 2015.

41. Rivera-Baez L, Lin E, Yoon H, Waghray M, Fouladdel S, Azizi E, Wicha M, Simeone D, Nagrath S. Application of label-free microfluidic technologies for the enrichment, expansion and characterization of circulating tumor cells in pancreatic cancer. Cancer Research, 75(15):1594, 2015.

42. Luo M, Davis A, McDermott S, Jiagge E, Brooks M, Gheordunescu E, Luther T, Clouthier S, Conley S, Spitz D, Wicha M. Targeting EMT and MET breast cancer stem cell states through simultaneous inhibition of glycolytic and antioxidant pathways. Cancer Research, 75(15):2311, 2015.

43. Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE. A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors. Cancer Research, 76(2):480-490, 2016.

Max Wicha, MD 29

Chapters in Books and Review Articles

1. Kidwell WE, Wicha MS, Salomon D, Liotta LA: Hormonal control of collagen substratum formation by cultured mammary cells: Implications for growth and differentiation. In Control in Animal Cells. Jimenez de Asua, Levi-Montalcini R, Shields R, Iacobelli S: (Eds.), Raven Press, pp. 333-340, 1981.

2. Kidwell WR, Wicha MS, Salomon D, Liotta LA: Differential recognition of basement membrane collagen by normal and neoplastic mammary cells. In Systematics of Mammary Cell Transformation. McGrath and Mandi (Eds.), Academic Press, 1980.

3. Liotta A, Garbisa S, Tryggason K, Wicha MS: Correlation of metastatic behavior with tumor cell degradation of basement membrane collagen. In Tumor Progression. Crispen R (Ed.), Chicago, 1980.

4. Kidwell WR, Wicha MS, Liotta LA: Identification of mammary cell types. In Cell Biology of Breast Cancer. McGrath C, Brennan M, Rich M (Eds.), Academic Press, 1980.

5. Wicha MS: Interaction of rat mammary epithelium with extracellular matrix components. In New Approaches to the Study of Benign Prostatic Hyperplasia. Kimball F, Buhl A, Carter D (Eds.), A.R. Liss, New York, pp 129-142, 1984.

6. Blum JL, Zeigler ME, Wicha MS: Extracellular matrix: structure, biosynthesis and role in mammary differentiation. In Cellular and Molecular Biology of Experimental Mammary Cancer. 1986.

7. Cody RL, Wicha MS: Contemporary chemotherapy of breast cancer. In Breast Cancer: Collaborative Management. Harness JK, Oberman HA, Lichter AS, Adler DD, Cody RL (Eds.), Lewis Publishers, Inc., Chelsea, MI, pp 157-177, 1988.

8. Zeigler ME, Blum JL, Cody RL, Wicha MS: Basement membrane regulation of milk protein gene expression. In Growth and Differentiation of Mammary Epithelial Cells in Culture. Enami J, Ham R (Eds.), Japan Scientific Societies Press, Tokyo, pp 187-206, 1987.

9. Campbell AD, Wicha MS: Hematopoietic system. In Clinical Diagnosis. Fifth Edition, Judge RD, Zuidema GD, Fitzgerald FT (Eds.), Little, Brown and Company, Chapter 7. pp 101-112, 1988.

10. Blum JL, Zeigler M, Wicha MS: Regulation of mammary differentiation by the extracellular matrix. In Monograph on Regulation of Differentiation in Eukaryotic Cells. A. M. Jetten, (Ed), Environmental Health Perspectives publishers Vol 80, pp 71-83, 1989.

11. Bissell MJ, Wicha MS: Extracellular matrix is required for milk protein gene expression & secretion in mammary epithelial cells. In The Biology of Lactation. Houdebine, (Ed)

12. Campbell AD, Sullenbarger BS, Long MW, Bahou W, Wicha MS: Hemonectin, a novel hematopoietic adhesion molecule. In, Dainiak N. The Biology of Hematopoiesis. Alan R. Liss, Inc., Vol 352, July 1989.

13. Wicha MS, Campbell AD: Cell adhesion mediated by matrix components of bone marrow. In Extracellular Matrix. Marcel Dekker, Inc., pp. 491-505, 1993.

Max Wicha, MD 30

14. Campbell A, Wicha MS, Long MW: Hemonectin, a granulocytic cytoadhesion molecule. In Long MW, and Wicha MS (Eds.), The Hematopoietic Microenvironment. Johns Hopkins University Press, pp. 177-189, 1993.

15. Sumantran VN, Wicha MS: Regulation of tumor cell growth, Clinical Oncology, pp 77-89, edited by Abeloff MD, Armitage JO, Lichter AS and Niederhuber JE. Churchill Livingstone Publishers, NY, NY. 1994.

16. Wicha M. Cell growth, differentiation and death, Kelley’s Textbook of Internal Medicine, Fourth Edition, Lippincott Williams & Wilkins, Philadelphia, PA. 2000.

1. Sumantran VN, Beidler DR, Wicha MS. Role of apoptosis and its modulation by Bcl-2 family members in breast and prostate cancer. Contemporary Endocrinology: Endocrine Oncology, 2000.

2. Mantle I, Dontu G, Liu S, Wicha MS. Cancer Stem Cells: Implications for Development of More Effective Therapies. Cancer Drug Resistance, 2006.

3. Balicki D, Leyland-Jones B, Wicha MS. Breast cancer stem cells and their niche: Lethal seeds on lethal soil. Pharmacogenetics of Breast Cancer: Towards the Individualization of Therapy. Macmillan Publishing Solutions, pp. 189-219, 2008.

4. Ginestier C, Wicha MS. Stem cells in breast development and carcinogenesis: Concepts and clinical perspectives. Diseases of the Breast, Fourth Edition. Lippincott Williams & Wilkins, Philadelphia, PA., pp. 22-28, 2009.

5. Wicha M, Barsky SF. Stem Cells, the Breast, and Breast Cancer. The Breast: Comprehensive Management of Benign and Malignant Diseases, Fourth Edition. Saunders Elsevier, Philadelphia, PA., pp.533-547, 2009.

6. D’Angelo R. and Wicha M. Stem Cells in Normal Development and Cancer. Progress in Molecular Biology and Translational Science, Volume 95. Elsevier Inc., San Diego, CA., pp. 113-158, 2010.

7. McDermott SP and Wicha MS. Cancer Stem Cells. Targeting Different States of Breast Cancer Stem Cells. Wiley Press, Hoboken, NJ, ISBN 978-1-118-35616-6, 2014

8. Ouzounova M, Liu S, Wicha MS. Stem cells in breast development and carcinogenesis: Concepts and clinical perspectives. Diseases of the Breast, Fifth Edition. Wolters Kluwer. Philadelphia, PA. ISBN/ISSN: 978-1-4511-86277, 2014.

9. Azizi E, Nagrath S, Kozminsky M and Wicha M. Molecular markers, isolation techniques and clinical implications. Current Cancer Series: Circulating Tumor Cells Cancer Stem Cells (ed. Richard Cote and Ram Datar). Springer Science, New York, pp. 75-97.

10. Luo M, Clouthier S.G., Azizi E, Wicha, M. Mammary Stem Cells (ed. Maria Vivanco), BSCSs: Current advances and clinical implications. In Press.

11. Malik F, Korkaya H, Wicha MS. Principles of Stem Cell Biology and Cancer: Future Applications and Therapeutics, First Edition. In Press.

12. Hu Y, Lu L, Xia Y, Chen X, Chang A, Hollingsworth R, Hurt E, Owen J, Moyer J, Prince M, Dai F, Bao Y, Wang Y, Whitfield J, Xia J, Huang S, Wicha M, Li Q. Therapeutic efficacy

Max Wicha, MD 31

of cancer stem cell vaccines in the adjuvant setting. Cancer Research, 76(16):4661-72 2016, Aug 15. doi: 10.1158/0008-5472.CAN-15-2664. PMID: 27325649

13. Paholak H, Stevers N, Chen H, Burnett J, He M, Korkaya H, McDermott S, Deol Y, Clouthier S, Luther T, Li Q, Wicha MS, Sun, D. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated phototermal therapy. Biomaterials, 104:145-57, 2016 June 23. doi: 10.1016/j.biomaterials.2016.06.045. PMID: 27450902

14. Chen Y, Zhang Z, Fouladdel S, Deol Y, Ingram P, McDermott S, Azizi E, Wicha M, Yoon E. Single Cell Dual Adherent-Suspension Co-Culture Micro-Environment for Studying Tumor-Stormal Interactions with Functionally Selected Cancer Stem-like Cells. Lab Chip, 16, 2935-2945, 2016. PMID: 27381658

15. Chen Y, Ingram P, Fouladdel S, McDermottS, Azizi E, Wicha M, Yoon E. High-Throughput Single-Cell Derived Sphere Formation for Cancer Stem-Like Cell Identification and Analysis. Scientific Reports, 6, 27301. 2016. PMID: 27292795

16. Sun L, Burnett J, Gasparyan M, Xu F, Jiang H, Lin C, Myers I, Korkaya H, Liu Y, Connarn J, He H, Zhang N, Wicha M, Sun D. Novel Cancer Stem Cell Targets during Epithelial to Mesenchymal Transition in PTEN-deficient Trastuzumab-resistant. Breast Cancer. Oncotarget. 2016 Jun 6. doi: 10.18632/oncotarget.9839. PMID: 27285982

17. Colacino JA, McDermott SP, Sartor MA, Wicha MS, Rozek LS. Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention. Breast Cancer Research and Treatment, pp 1-13, June 15, 2016. PMID: 27306423

18. Hsu E, Kulp S, Huang H, Tu H, Chao M, Tseng Y, Yang M, Salunke S, Sullivan N, Chen W, Zhang J, Teng C, Fu W, Sun D, Wicha M, Shapiro C, Chen C. Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis, 37(4) pp 430-442, April 1, 2016. PMID: 26905583

19. Finkel K, Warner, Kerk S, Bradford C, McLean S, Prince M, Zhong H, Hurt E, Hollingsworth R, Wicha M, Tice D, Nör J. IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence. Neoplasia, 18(5) pp 273-281, May 31, 2016. PMID: 27237319

20. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, Wan S, Wei S, Wang Y, Liu Y, Staroslawska E, Szubstarski F, Rolinski J, Grywalska E, Stanisławek A, Polkowski W, Kurylcio A, Kleer C, Chang A, Wicha M, Sabel M, Zou W, Kryczek I. Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 76 (11) pp 3156-3165, June 1, 2016. PMID: 27197152

21. Murthy P, Kidwell KM, Schott AF, Merajver SD, Griggs JJ, Smerage JD, Van Poznak CH, Wicha MS, Hayes DF, Henry NL. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 2016 Feb 13. PMID: 26875184

Max Wicha, MD 32

22. Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, Burness ML, Azizi E, Simeone D, Wicha MS, Kim J, Nagrath S. Efficient capture and release of circulating tumor cells by temperature-sensitive polymer-graphene oxide composite. Advanced Materials, 2016 Apr 26; DOI:10.1002/adma.201600658, 2016. PMID: 27115557

23. Jack R, Grafton M, Rodrigues D, Giraldez M,Griffith C, Cieslak R, Zenali M, Kumar-Sinha C, Azizi E, Wicha M, Tewari M, Simeone D, and Nagrath S. Ultra-Specific Isolation of Circulating Tumor Cells Enables Rare-Cell RNA Profiling. Advanced Science, DOI: 10.1002/advs.201600063, 2016.

24. Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE. A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including

25. Azizi, E, Harouaka R, Wicha MS, Granger J, Luther T. Stem Cells in Breast Development and Cancer. The Breast, January 2018, Online 2017.

Books or Journals Edited

1. Long MW and Wicha MS (Eds.). The Hematopoietic Microenvironment. Johns Hopkins University Press (multi-author text). 1993

2. Wicha MS (Assoc Editor). Molecular and Cellular Differentiation. CRC Press, 1993 INVITED LECTURES 1982 Warner-Lambert Symposium; Non-Cytotoxic approaches to chemotherapy. 1982 Cell Biology Meeting; Modulation f mammary epithelial growth and differentiation by

mammary biomatrix, Baltimore, MD. 1983 Extracellular Matrix Symposium; Chairman and speaker; AACR meeting. San Diego,

CA. 1983 Oncology Viewpoints; The importance of receptors in predicting breast cancer response

to hormonal therapies; Mead Johnson Publishing. 1983 Conference of Prostatic Hyperplasia; Interactions of hormones and extracellular matrix in

the control of mammary growth and differentiation; Upjohn Company. 1984 European Society of Cell Biology; New systems for the study of mammary growth and

differentiation; Manchester, England. 1984 Gordon Conference on Basement Membranes; Connectin, a cell surface protein that binds

both laminin and actin; Andover, New Hampshire. 1984 Tissue Culture Society Meeting; Extracellular matrix and mammary function; Houston,

TX. 1984 Pulmonary Biology Gordon Research Conference; Modulation of mammary growth and

differentiation by extracellular matrix components; New Hampshire. 1985 Visiting Professor, Michigan State University; Molecular biology of cancer; Lansing, MI. 1985 Intl Tissue Culture Meeting; Molecular mechanisms involved in modulation of mammary

gene expression by extracellular matrix; Sendai, Japan.

Max Wicha, MD 33

1985 American Society for Cell Biology; Regulation of mammary gene expression by extracellular matrix; New Orleans, LA.

1986 Visiting Professor, Harvard University, Boston, MA. 1986 Visiting Professor, Washington State University. 1986 Visiting Professor, Boston University. 1986 First Conference on Differentiation Therapy; Regulation of rat mammary gene expression

by extracellular matrix components and the cytoskeleton; Villasimius, Cagliari, Sardinia. 1987 Visiting Professor, Medicine Grand Rounds and Medical Oncology Grand Rounds;

Wayne State University/Harper Grace Hospitals. 1987 Visiting Professor, Department of Physiology and Biophysics, University of Illinois; Role

of the extracellular matrix and the cytoskeleton in the regulation of mammary gene expression; Chicago, IL.

1987 Gordon Research Conference; Effects of extracellular matrix on mammary gene expression; New London, NH.

1987 Visiting Professor, Department of Hematology/Oncology, Medical College of Wisconsin; Metastases and the extracellular matrix; Milwaukee, WI.

1987 Visiting Professor, Evan and Marion Helfaer Foundation Distinguished Lectureship Series, Medical College of Wisconsin Cancer Center; Regulation of gene expression by extracellular matrix components; Milwaukee, WI.

1987 Second Conference on Differentiation Therapy; Cell biology of differentiation therapy: cell-cell interaction; South Hampton, Bermuda.

1987 Visiting Professor, University of Chicago. 1987 American Federation for Clinical Research Lecture. 1988 Visiting Professor, The Eppley Institute for Research n Cancer and Allied Diseases; The

role of the extracellular matrix and cytoskeleton in cellular differentiation; Omaha, NE. 1988 Visiting Professor, The University of Nebraska, Omaha, NE. 1988 Third Conference on Differentiation Therapy of Cancer; Villasimius, Cagliari, Sardinia. 1988 Visiting Professor, The University of Minnesota and The Minneapolis Veterans

Administration Hospital. 1988 Co-Chairperson, Hematology and Oncology II, American Federation for Clinical

Research, Chicago, IL. 1989 Visiting Professor, MD Anderson Cancer Center, Houston, TX. 1989 Visiting Professor, Mt Sinai Medical Center, New York, NY 1989 American Cancer Center; Overview of current research; Lansing, MI. 1989 Visiting Professor, American Cancer Society, Kalamazoo, MI. 1990 Visiting Professor, American Cancer Society; Mammastatin, mammography specific

growth inhibitors; Gainesville, FL. 1990 Visiting Professor, American Cancer Society; The role of the extracellular matrix in

hematopoiesis; Miami, FL. 1990 Visiting Professor, American Cancer Society; Growth factors in breast cancer, Orlando,

FL. 1990 First Annual Breast Oncology Research Retreat; mammastatin and the extracellular

matrix; University of Michigan, Ann Arbor, MI. 1990 Cancer Cell Biology Workshop, Washington, D.C. 1990 American Society of Clinical Oncology, Washington, D.C. 1990 Visiting Professor, Pezcoller Symposium; Growth inhibitors; Rovereto, Italy.

Max Wicha, MD 34

1990 FASEB Federation of American Societies for Experimental Biology; Mammastatin: a mammary growth inhibitor; Saxton’s River, Vermont.

1990 Guest Speaker, Canton Rotary Club; University of Michigan Cancer Center; Canton MI. 1990 Gordon Conference on Cancer Chemotherapy; Mammastatin: a tissue specific inhibitor of

breast cancer cell growth; New London, NH. 1990 Fourth Annual Symposium on Breast Disease; Mammary growth factors: implications for

development of new breast cancer treatment; Grand Traverse, MI. 1990 Sixth International Conference on Differentiation of Normal and Neoplastic Cells;

mammastatin: a growth inhibitor of human breast cancer cells; Vancouver, B.C., Canada. 1990 Visiting Professor, Prince Henry’s Hospital; The role of extracellular matrix in the

hematopoietic microenvironment; Biology of breast cancer; Breast cancer and the bone marrow microenvironment; Melbourne, Australia.

1990 Visiting Professor, Northwestern University Medical Center; Regulation of normal and malignant mammary growth; Chicago, IL.

1990 Visiting Professor, Medical Grand Rounds; Regulation of normal and malignant mammary growth; Memorial Sloan-Kettering Cancer Center, New York.

1990 Visiting Professor, Texas Southwestern University; Mammastatin: a physiologic mammary growth inhibitor; Dallas, TX.

1990 Lecturer, Anatomy and Cell Biology; Interaction of extracellular matrix with epithelial cells; The University of Michigan; Ann Arbor, MI.

1990 Forty-third Annual Symposium of Fundamental Cancer Research; Mammastatin and antiproliferative proteins and adhesion molecules in breast cancer; MD Anderson Cancer Center; Houston, TX.

1991 Breast Cancer Symposium; Mammastatin: a physiologic growth inhibitor; Denver, CO. 1991 Visiting Professor and Cancer Center Review; Growth factors in mammary carcinoma

development; Michigan State University; Lansing, MI. 1991 Visiting Professor, Ireland Cancer; Mammastatin: a physiologic mammary growth

inhibitor; Cleveland, OH. 1991 First Annual Symposium Molecular Basis of Cancer Therapeutics; Mammastatin: a

physiologic mammary growth inhibitor; Lineberger Cancer Research Center; Chapel Hill, NC.

1991 American Association for Clinical Research; Mammastatin: a mammary growth regulator; Houston, TX.

1991 American Society of Clinical Oncology; Houston, TX. 1991 Gordon Conference on Mammary Gland Biology; Mammastatin: a specific inhibitor of

mammary tumor development; Colby-Sawyer College, New London, NH. 1991 NIH Symposium; Hemonectin: a specific adhesion molecule in the microenvironment;

Bethesda, MD 1991 University of Chicago; The role of growth factors in normal and malignant mammary

growth; Chicago, IL. 1992 Breast and Prostate Symposium; Mammastatin: a physiologic inhibitor of mammary cell

growth; Lake Tahoe, CA. 1992 Cold Spring Harbor Laboratory; Mammary growth inhibitors; Cold Spring Harbor, NY 1992 Community Health Center of Branch County; Advances in breast cancer research;

Coldwater, MI 1993 Strattton V.A. Medical Center; Breast cancer biology: molecular insights; Albany, NY

Max Wicha, MD 35

1994 Keynote speaker, Markey Cancer Center Special Seminar Series; Breast cancer biology: implications for diagnosis and treatment; Lexington, KY.

1994 David Perlman Memorial Lecturer; Breast cancer biology: implications for prevention and therapy; Univ of Wisconsin; Madison, WI.

1994 Nutrition and Cancer Conference; Mechanisms of action in carcinogenesis; Ann Arbor, MI

1995 University of Indiana; Insights into the biology of breast cancer: therapeutic implications; Indianapolis, IND

1995 Breast Cancer Think Tank 5 Symposium; Apoptosis in breast cancer: clinical implications; Nassau, The Bahamas

1995 National Cancer Institute Cancer Center Directors’ Workshop; Function of the parent committee in budget control of the cancer centers; Washington, D.C.

1995 National Cancer Advisory Board Annual Meeting, Mini-Symposium: Cancer Centers: Evolution into The 21st Century; Matrix cancer centers; Washington, D.C.

1995 Greater Detroit Area Health Council, Coffee and Controversy; Collaboration or competition: the future of cancer care in southeast Michigan; Detroit, MI

1996 Breast Cancer Symposium Think Tank 6; Targeting cell death pathways for breast cancer therapy; Curacao

1996 Michigan Department of Public Health Annual Health Facilities Planning Seminar; Directions in Cancer Research/Treatment; Bellaire, MI

1996 American Association for Cancer Research Eighty-seventh Annual Meeting; Co-Chair Poster Discussion Session; Therapy Directed Apoptosis.

1996 Women’s Health and Life Forum; Breast cancer diagnosis, treatment and prevention; Dearborn, MI.

1996 Multigene Interactions Study Group; Selective targeting of apoptosis pathways for cancer therapy; Woods Hole, MA.

1996 University of Massachusetts Cancer Center Distinguished Lecture Series; Targeting apoptosis pathways for breast cancer therapy; Wooster, MA

1996 American Cancer Society Seventh Annual Cancer Research Conference, Mini-Symposium: Innovations in Breast Cancer; Apoptotic approaches to breast cancer therapy; Ann Arbor, MI

1997 Breast Cancer Symposium Think Tank 7; Targeting apoptotic pathways for breast cancer treatment, St Lucia

1997 Grand Rapids Area Medical Education Consortium, OB/GYN Visiting Professor; New directions in breast cancer research, Breast cancer genetics; Grand Rapids, MI

1998 Breast Cancer Symposium Think Tank 8; Targeting cell death pathways for breast cancer therapy; Coco Reef, Tobago

1998 National Breast Cancer Coalition Fund Sixth Annual Advocacy Training Conference, Workshop leader; Clinical trials and informed consent; Washington, DC

1998 Visiting Professor, Breast cancer research; Chinese Academy of Medical Sciences & Peking Medical College, Beijing, China; Zhejing Medical University Cancer Research Center & Hospital, Hang Zhou, China; Oncology Research Institute & Hospital, Shanghai Medical University, Shanghai, China.

1998 Invited Discussant, Current Topics in Breast Cancer Research III, Cell Death in Breast Cancer; Cambridge, England

1998 Panel Member, President’s Cancer Panel meeting; Buffalo, NY

Max Wicha, MD 36

1998 21st San Antonio Breast Cancer Symposium; The prospects for development of gene therapy for treatment and prevention of breast cancer; San Antonio, TX

1999 Breast Cancer Symposium Think Tank 9; Targeting cell death pathways for breast cancer therapy; St Thomas, US Virgin Islands

1999 American Association for Cancer Research 90th Annual Meeting; The challenge and promise of university based cancer centers; Philadelphia, PA

2000 Distinguished Lecturer, The Cancer Institute of New Jersey; Targeting cell death pathways for breast cancer therapy; New Brunswick, NJ

2000 Blood Club Seminar, Ireland Cancer Center; Targeting cell death pathways for breast cancer therapy; Cleveland, OH

2001 Breast Cancer Symposium Think Tank 11; Breast Stem Cells; Punta Cana, Dominican Republic

2001 Keynote Speaker, Association of Cancer Executives 7th Annual Meeting; Visualizing the cancer center of the future; Washington, D.C.

2001 Spectrum Health Combined Breast Tumor/Plastic Surgery Grand Rounds; Advances in breast cancer research; Grand Rapids, MI

2001 Lombardi Cancer Center Oncology Grand Rounds; Stem cells in the mammary gland; Washington, D.C.

2002 Breast Cancer Symposium Think Tank 12; Stem cells for the normal breast; St Maarten, Netherlands Antilles

2002 Gordon Research Conference on Mammary Gland Biology; Breast stem cells; Lucca, Italy

2002 Baylor College of Medicine Breast Seminar series; Human mammary stem cells; Houston, TX

2002 McArdle Laboratory for Cancer Research Grand Rounds and Colloquium; Human mammary stem cells; Madison, WI

2003 MD Anderson Cancer Center Women’s Cancer Research Group; Stem cells in the normal and cancerous breast; Houston, TX

2003 Moffitt Cancer Center Grand Rounds, Stem cells in the normal and cancerous breast, Tampa FL

2003 Lawrence Berkeley National Laboratory, Stem cells in Normal breast development and breast cancer, Berkeley, CA

2003 Van Andel Cancer Research Institute, Stem cells in the normal and cancerous breast, Grand Rapids, MI

2003 University of Nebraska Grand Rounds, Stem cells in the normal and cancerous human breast, Omaha, NE

2003 ENDO conference, Mammary stem and progenitor cells in breast cancer, Philadelphia, PA

2003 Canadian Breast Cancer Initiative, Mammary stem cells in the normal and cancerous breast, Toronto, Ontario

2003 IABCR, Stem cells in normal breast development and breast cancer, Sacramento, CA 2003 San Antonio Breast Cancer Symposium, Stem cells in the normal and cancerous human

breast, San Antonio, TX 2004 Breast Cancer Symposium Think Tank 14, Regulation of mammary stem cell self-

renewal and differentiation, St. Kitts 2004 Expedition Inspiration, Sun Valley, ID

Max Wicha, MD 37

2004 Susan Love Breast Cancer Conference, Stem cells in the normal human breast, Santa Barbara, CA

2004 Ben May Symposium: Stem Cells Cancer and Development, Stem Cells in the Normal and Cancerous Human Breast, Chicago, IL

2004 Cancer Research UK, Stem Cells in Normal Human Breast Development and Cancer, London, UK

2004 NSABP, Stem Cells in Normal and Cancerous Human Breast Cancer, Toronto, Ontario 2004 Aspen Cancer Conference, Stem Cells in Normal Human Breast Development and

Cancer: Implications for Prevention and Therapy, Aspen, CO 2005 Weizmann Institute Seminar Series, Tel Aviv, Israel 2005 Keystone Symposia, Breast Cancer Ste Cells: Implications for Early Detection &

Therapy, Santa Barbara, CA 2005 Vanderbilt-Ingram Cancer Center Seminar Series, Nashville, TN 2005 Van Andel Institute Han-Mo Koo Seminars, Stem Cells in Normal Human Breast

Development & Cancer Implications for Prevention & Therapy, Grand Rapids, MI 2005 Cancer Education Consortium/Astrazeneca, Stem Cells and Cancer, Amelia Island, FL 2005 American Association of Cancer Research, 96th Annual Meeting, Stem Cells, Metastasis,

and Residual Disease: Integrating New Findings in Breast Cancer Research, Anaheim, CA

2005 Era of Hope 2005 – Department of Defense Breast Cancer Research Program, Stem cells in Normal Human Breast Development and Cancer: Therapeutic Implications, Philadelphia, PA

2005 Scientific Review of the Samuel Waxman Cancer Research Foundation Supported Programs, Stem Cells in Normal Mammary Development and Breast Cancer, New York, NY

2005 3rd International Symposium on “The Molecular Biology of Breast Cancer”, Stem Cells in Human Breast Development and Cancer, Oslo, Norway

2005 NCI Center for Cancer Research Grand Rounds, Stem Cells in Normal Mammary Development and Breast Cancer, Bethesda, MD

2005 The Burnham Institute Oncology Seminar Series, Breast Cancer Stem Cells – Implications for Prevention and Therapy, LaJolla, CA

2006 Dana Farber Cancer Institute Seminars in Oncology, Breast Cancer Stem Cells – Implications for Prevention and Therapy, Boston, MA

2006 Breast Cancer Symposium “Think Tank 16”, Role of Hedgehog & Bmi-1 in Mammary Stem Cell Self-renewal, Grand Cayman

2006 European Cancer Centre Breast Cancer: From Gene to Cure, Mammary Stem Cells: Targets for Transformation, Amsterdam, The Netherlands

2006 Mayo Clinic Grand Rounds, Stem Cells in Brest Development in Cancer: Implications for Cancer Prevention and Therapy, Rochester, MN

2006 Vermont Cancer Center Distinguished Lecture Series, Stem Cells in Mammary Development and Cancer: Implications for Prevention and Therapy, Burlington, VT

2006 5th European Breast Cancer Conference, Stem Cells in Mammary Development and Cancer: Implications for Prevention and Therapy, Nice, France

2006 American Association of Cancer Research – 97th Annual Meeting, Notch, Hedgehog, and Wnt Signaling Pathways in Cancer, Washington, DC

Max Wicha, MD 38

2006 Ohio State University Comprehensive Cancer Center Grand Rounds, Breast Cancer Stem Cells: Implications for Prevention and Therapy, Colombus, OH

2006 Ettore Majorana Foundation and Centre for Scientific Culture Advanced Course on Estrogens and Human Diseases, Estrogen Effects on Human Mammary Stem and Progenitor Cells, Erice, Italy

2006 Woodward Visiting Professor Lecture Memorial Sloan Kettering Cancer Center Grand Rounds, Self-Renewal Pathway in Normal and Malignant Human Mammary Stem Cells, New York, NY

2006 Ira B. Black Memorial Lecture Address at Cancer Institute of New Jersey Annual Statewide Retreat on Cancer, Breast Cancer Stem Cells: Implications for Prevention and Therapy, New Brunswick, NJ

2006 Fred Hutchinson/University of Washington Cancer Consortium Scientific Steering Committee Symposium, Stem cells in breast development and cancer: Implications for prevention and therapy, Seattle, WA

2006 Taussig Cancer Center/Cleveland Clinic Grand Rounds, Cancer Stem Cells: An Old Idea – A Paradigm Shift, Cleveland, OH

2006 Pfizer 3rd Annual Breast Cancer Think Tank, Cancer Stem Cells – The New Target in Cancer Treatment, New York, NY

2006 14th SPORE Investigators Workshop, Chair, Mini-Symposia, Tumor Cells and Lineage Dependencies, Baltimore, MD

2006 Cold Spring Harbor Laboratory Course, Cancer Stem Cells: An Old Idea – A Paradigm Shift, Cold Spring Harbor, NY

2006 4th International Meeting on Molecular Markers, Cancer Stem Cells: Diagnostic and Therapeutic Promises, Stone Mountain, GA

2006 25th Congress of International Association of Breast Cancer Research, Self-renewal Pathways in Normal and Malignant Mammary Stem Cells, Montreal Canada

2006 National Cooperative Drug Discovery Group Workshop, Update on Cancer Stem Cells, Houston, TX

2006 Tufts University Genetic Seminar Series, Stem Cells in Normal Breast Development and Breast Cancer, Boston, MA

2006 59th Annual Symposium on Cancer Research, Stem Cells in Normal Mammary Development in Carcinogenesis: Implications for Prevention and Therapy, Houston, TX

2006 NCI Tumor Stem Cell Retreat, Stem Cells in Normal Mammary Development and Breast Cancer: Implications for Prevention and Therapy, Bethesda, MD

2006 53rd Annual Meeting of the Radiation Research Society, Therapeutic Implications of the Cancer Stem Cell Hypothesis, Philadelphia, PA

2006 Cancer and Stem Cell Signaling Symposium, Breast Cancer Stem Cells: Implications for Prevention and Therapy, Albany, NY

2006 Frontiers in Cancer Prevention Research, Implications of the Cancer Stem Cell Hypothesis for Early Detection and Prevention, Boston, MA

2007 15th SPORE Workshop, Baltimore, MD 2007 AACR Annual Meeting, Los Angeles, CA 2007 American Pancreatic Association, Chicago, IL 2007 ASCO Annual Meeting, Chicago, IL 2007 Cold Spring Harbor Seminar, Cold Spring Harbor, NY 2007 Duke Comprehensive Cancer Center’s Breast Oncology Symposium, Durham, NC

Max Wicha, MD 39

2007 Workshop on Cancer Stem Cells, ESSM, Milan, Italy 2007 MetaBre/BRECOSM, Rome, Italy 2007 Fox Chase Cancer Center Symposium, Philadelphia, PA 2007 Gordon Conference-Hormone Action in Development & Cancer, Boston, MA 2007 Gordon Conference-Molecular Therapeutics of Cancer, New London, NH 2007 BRCA: New Frontiers in Research and Practice, Montreal, Canada 2007 VilleMarie Oncology Center, Montreal, Canada 2007 Jefferson University Kimmel Cancer Center Annual Symposium, Philadelphia, PA 2007 Lynn Sage Breast Cancer Symposium, Chicago, IL 2007 Merck Symposium, Rome, Italy 2007 CHO, Paris, France 2007 NBCCF, Chicago, IL 2007 NCCN 12th Annual Conference, Fort Lauderdale, FL 2007 2007 Fellow’s Retreat Keynote Lecture, Philadelphia, PA 2007 NCI Workshop, Washington, D.C. 2007 Skeletal Complications of Malignancy, The Paget Foundation, Philadelphia, PA 2007 UCLA Jonsson Cancer Center Seminar Series, Los Angeles, CA 2007 Wake Forest University, Deal Lectureship, Winston-Salem, NC 2007 San Antonio Breast Cancer Symposium, San Antonio, TX 2008 Stem Cell Workshop, Washington, D.C. 2008 Multiple Myeloma Research Foundation, New York, NY 2008 Gordon Research Conference, Ventura Beach, CA 2008 6th International Symposium on Targeted Anticancer Therapies, Bethesda, MD 2008 8th Annual New Strategies in Breast Cancer Conference, Philadelphia, PA 2008 American Association for Cancer Research, San Diego, CA 2008 Baba Memorial Lecture, Ohio State, Cleveland, OH 2008 NBCCF, Washington, DC 2008 SHARE, New York, NY 2008 American Society of Breast Surgeons, New York, NY 2008 NCCDO/PAN, Cedar Rapids, IA 2008 Whitehead Institute Retreat, Boston, MA 2008 UCSF Symposium, San Francisco, CA 2008 Cold Spring Harbor 73rd Annual Symposium, Cold Spring Harbor, NY 2008 American Society of Clinical Oncology, Chicago, IL 2008 George Washington Cancer Institute Grand Rounds, Washington, D.C. 2009 Beaumont Internal Medicine Grand Rounds, Royal Oak, MI 2009 Karmanos Cancer Institute Grand Rounds, Detroit, MI 2009 Mass General Hospital Cancer Center Grand Rounds, Boston, MA 2009 University of Iowa Interdisciplinary Graduate Program Workshop, Iowa City, IA 2009 New York Metropolitan Breast Cancer Group 36th Annual Symposium, New York, NY 2009 Eppely Cancer Center Grand Rounds, Omaha, NE 2009 Irish Association for Cancer Research Annual Meeting, Dublin, Ireland 2009 Primary Therapy of Early Breast Cancer Conference, St. Gallen, Switzerland 2009 Center for Biomedical Continuing Education, Philadelphia, PA 2009 University of Wisconsin Stem Cell Symposium, Madison, WI 2009 American Association for Cancer Research, Denver, CO

Max Wicha, MD 40

2009 NSABP Foundation, San Diego, CA 2009 American Society for Clinical Oncology, Orlando, FL 2009 Seminars in Oncology, Boston, MA 2009 Memorial Sloan Kettering, State of the Art Lectures, New York, NY 2009 Samuel Waxman Research Foundation, New York, NY 2009 NCI Lung Cancer Group, Bethesda, MD 2009 EDRN, Bethesda, MD 2009 MD Anderson Stem Cells and Caner Seminar Series, Houston, TX 2009 NFGC, Clearwater, FL 2009 AACR, San Diego, CA 2009 AIM Educational Conference, Philadelphia, PA 2009 International Conference on Differentiation Therapy, Chicago, IL 2010 Beth Israel Deaconess Grand Rounds, Boston, MA 2010 University of Minnesota Cancer Center Grand Rounds, Minneapolis, MN 2010 University of Pittsburgh Bernard Fisher Lecture, Pittsburgh, PA 2010 Scientific Program of the Foundation Ipsen Stem Cells and Cancer, Bariloche, Argentina 2010 Meet the Oncology Expert, Brussels, Belgium 2010 Cancer Biology Seminar, Stanford University, San Francisco, CA 2010 Department of Internal Medicine Seminar, Stanford University, San Francisco, CA 2010 AACR, Washington, D.C. 2010 Bristol-Meyers Squibb, Newark, NJ 2010 RRS: 56th Annual Meeting of the Radiation Research Society, Maui, HI 2010 World Stem Cell Summit, Detroit, MI 2010 Robert Krigel Endowed Lecture, Fox Chase, Philadelphia, PA 2010 AACR: Frontiers in Cancer Prevention, Philadelphia, PA 2010 Amazon Project, Palermo, Italy 2010 NYU Grand Rounds, New York, NY 2010 UCSD Grand Rounds, San Diego, CA 2010 Karmanos Cancer Institute Breast/Protease Retreat, Detroit, MI 2011 CNIO Frontiers meetings, Madrid, Spain 2011 Keystone Symposia, Keystone, Colorado 2011 Cancer Institute of New Jersey Stem Cell Symposium, New Brunswick, NJ 2011 AACR Annual Meeting, Orlando, FL 2011 ASCO Annual Meeting, Chicago, IL 2011 Cancer Stem Cell Program, University of Texas Medical Branch, Galveston, TX 2011 Stars in Nutrition, NIH, Rockville, MD 2011 AICR meeting, Washington, DC 2011 AACR, San Francisco, CA 2011 The 4th Guangzhou International Conference on Stem Cell Biology and Regenerative

Medicine, Guangzhou, China 2012 AACR, Philadelphia, PA 2012 Case Western Grand Rounds, Cleveland, OH 2012 University of Florida Grand Rounds, Gainesville, FL 2012 NCI-Frederick Distinguished Scientist Lecture Series, Frederick, MD 2012 AACR, Chicago, IL 2012 28th International Association for Breast Cancer Research, Manchester, England

Max Wicha, MD 41

2012 American Society of Breast Surgeons, Phoenix, AZ 2012 Saginaw County Medical Society Annual Membership meeting, Saginaw, MI 2013 Science of Medicine Lecture, Mayo Clinic, Scottsdale. AZ 2013 UCLA Honorary Lecture, UCLA, Los Angeles, CA 2013 15th International Symposium on Anti-angiogenic Therapy, La Jolla, CA 2013 Targeting Cancer Stem Cells, San Francisco, CA 2013 MD Anderson Seminar Series, MD Anderson, Houston, TX 2013 AACR annual meeting, Washington, DC 2013 Siteman Cancer Center Speaker Series, St. Louis, MO 2014 UCSD CC Directors Seminar, La Jolla, CA 2014 Florida Hospital Distinguished Lecture Series, Orlando, FL 2014 NMTRC Symposium, Grand Rapids, MI 2014 Northwestern University Seminar Series, Chicago, IL 2014 7th Annual Breast Cancer Symposium, Peoria, IL 2014 EMBO CSC Workshop, Catanzaro, Italy 2014 ACTC, Heraklion, Greece 2014 SWOG Group meeting, Chicago, IL 2014 Xiangshang-Science Conferences, Beijing, China 2015 AACR Radiation Oncology Think Tank, Chicago, IL 2015 Verastem Seminar, Boston, MA 2015 London Regional Cancer Program, London, Ontario 2015 SSO/ACS Annual meeting, Houston, TX 2015 MedImmune Advisory Board, Gaithersburg, MD 2015 AACR annual meeting, Philadelphia, PA 2015 ASCO annual meeting, Chicago, IL 2015 AACC annual meeting, Atlanta, GA 2015 PTC Therapeutics, New Brunswick, NJ 2015 MedImmune CSC Symposium, Gaithersburg, MD 2015 CNIO Frontiers meeting, Madrid, Spain 2015 Manchester Br Center Annual Symposium, Manchester, England 2015 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 2016 Yale Cancer Center Grand Rounds, Julia & Patricia Kingsbury Memorial Lectureship:

Clinical Implications of Cancer Stem Cells, New Haven, CT 2016 GRU Science Lecture Series, Targeting Breast Cancer Stem Cells, Augusta, GA 2016 The Osher Lifelong Learning Institute, “BioMedical Breakthrough: The Future is Here”,

series, Can We Really Cure Cancer? Ann Arbor, MI 2016 10th ISMRC, International Symposium on Minimal Residual Cancer: Liquid Biopsy in

Cancer Diagnostics and Treatment, Molecular Analysis of Circulating Breast Cancer Stem Cells, Hamburg, Germany

2016 PEGS: the essential protein engineering summit, Therapeutic Targeting of Breat Cancer Stem Cells, Boston, MA

2016 University of Iowa HCCC Research Retreat, Keynote presentation: Challenges and Opportunities in Targeting Cancer Stem Cells, Iowa City, IA

2016 Cancer Stem Cell Conference, Targeting Breast Cancer Stem Cells, Cleveland, OH 2016 Jensen Symposium, Targeting Breast Cancer Stem Cells, Cincinnati, OH

Max Wicha, MD 42

2016 San Antonio Breast Cancer Conference, Targeting Breast Cancer Stem Cells, San Antonio, TX

2016 American Society of Cell Biology, Mechanistic Underpinnings of Cancer Stem Cell State Transitions, San Francisco, CA

2017 Breast Cancer Think Tank 27, Epigenetic regulation of breast cancer stem cells, Labrelotte Bay Castries, St. Lucia

2017 Molecular Medicine TriCon 2017 Seventh Annual Circulating Tumor Cells and Liquid Biopsy Conference, Isolation and molecular characterization of breast cancer stem cells,

San Francisco, CA 2017 National Cancer Institute Center for Cancer Research, CCR Eminent Lecture, Targeting

Breast Cancer Stem Cells: Challenges and Opportunities, Bethesda, MD 2017 Roswell Park Cancer Institute Experimental Therapeutics Conference, Targeting Breast

Cancer Stem Cells: Challenges and Opportunities, Buffalo, NY RESEARCH INTERESTS Mammary cell biology - Regulation of mammary growth, differentiation and apoptosis - Stem cells in normal mammary development and breast cancer - Cancer stem cell therapeutics CLINICAL SPECIALTY Medical Oncology